2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T899,Understanding which children present with skin disease and reach specialty care is essential for characterizing patterns of disease frequency and care use. To describe the frequencies of common pediatric skin diseases and patterns of dermatology use, stratified by race and ethnicity, across 8 US children's hospitals participating in the PEDSnet system. This was a multicenter cross-sectional study of 8 US children's hospitals in PEDSnet from January 2009 to July 2022. Data were analyzed from January 3 to March 26, 2024. The study cohort included children with 1 or more dermatology clinic visit or 2 or more non-dermatology clinic visits coded for atopic dermatitis (AD), acne, infantile hemangioma, psoriasis, or hidradenitis suppurativa (HS). Disease frequency per 100 000 children and proportion of children using dermatology care for each condition, stratified by race and ethnicity. Of 536 776 patients, the mean (SD) age was 6.4 (6.3) years, 51.5% were female, and 0.2% were American Indian or Alaska Native, 6.4% Asian, 27.9% Black, 14.1% Hispanic, 0.3% Native Hawaiian or Other Pacific Islander, 8.4% non-Hispanic, 44.3% White, 4.3% multiple races, 5.5% unknown ethnicity, and 16.6% unknown race. Case counts were 377 970 for AD, 139 632 for acne, 54 305 for infantile hemangioma, 11 339 for psoriasis, and 5722 for HS. Electronic health record-derived frequencies varied across race and ethnicity groups. There were 10 469 (95% CI, 10 414-10 524) cases of AD per 100 000 Black children compared with 3099 (95% CI, 3083-3114) per 100 000 White children. There were 290 (95% CI, 280-300) cases of infantile hemangioma per 100 000 Black children compared with 764 (95% CI, 756-772) per 100 000 White children. Black children had a low proportion of dermatology use across all 5 conditions, yet high frequencies of AD, acne, and HS. In this study, across all studied conditions, Black children had a low proportion of dermatology use at participating PEDSnet US children's hospitals, despite having high frequencies of AD, acne, and HS. Further research is required to determine whether these patterns represent appropriate specialty care use or reflect gaps in care.31:Tccc, Importance Understanding which children present with skin disease and reach specialty care is essential for characterizing patterns of disease frequency and care use. Objective To describe the frequencies of common pediatric skin diseases and patterns of dermatology use, stratified by race and ethnicity, across 8 US children’s hospitals participating in the PEDSnet system. Design, Setting, and Participants This was a multicenter cross-sectional study of 8 US children’s hospitals in PEDSnet from January 2009 to July 2022. Data were analyzed from January 3 to March 26, 2024. The study cohort included children with 1 or more dermatology clinic visit or 2 or more non–dermatology clinic visits coded for atopic dermatitis (AD), acne, infantile hemangioma, psoriasis, or hidradenitis suppurativa (HS). Main Outcomes and Measures Disease frequency per 100 000 children and proportion of children using dermatology care for each condition, stratified by race and ethnicity. Results Of 536 776 patients, the mean (SD) age was 6.4 (6.3) years, 51.5% were female, and 0.2% were American Indian or Alaska Native, 6.4% Asian, 27.9% Black, 14.1% Hispanic, 0.3% Native Hawaiian or Other Pacific Islander, 8.4% non-Hispanic, 44.3% White, 4.3% multiple races, 5.5% unknown ethnicity, and 16.6% unknown race. Case counts were 377 970 for AD, 139 632 for acne, 54 305 for infantile hemangioma, 11 339 for psoriasis, and 5722 for HS. Electronic health record–derived frequencies varied across race and ethnicity groups. There were 10 469 (95% CI, 10 414-10 524) cases of AD per 100 000 Black children compared with 3099 (95% CI, 3083-3114) per 100 000 White children. There were 290 (95% CI, 280-300) cases of infantile hemangioma per 100 000 Black children compared with 764 (95% CI, 756-772) per 100 000 White children. Black children had a low proportion of dermatology use across all 5 conditions, yet high frequencies of AD, acne, and HS. Conclusions and Relevance In this study, across all studied conditions, Black children had a low proportion of dermatology use at participating PEDSnet US children’s hospitals, despite having high frequencies of AD, acne, and HS. Further research is required to determine whether these patterns represent appropriate specialty care use or reflect gaps in care. 32:T834,Latine patients with hidradenitis suppurativa (HS) are reported to experience more severe disease and longer delays to diagnosis compared with White patients with HS. To assess the implications of health care system factors in HS care experiences for Latine patients. From June 2024 through March 2025, this qualitative study recruited English- and Spanish-language preferring Latine adults diagnosed with HS from dermatology clinics at 2 academic medical centers and 2 county hospitals in California. Deidentified audio recordings were transcribed and translated from semistructured interviews conducted by a bilingual Latine interviewer. After transcripts were coded, a thematic analysis was conducted to develop themes that captured the range of participants' experiences, attitudes, behaviors, and beliefs related to receiving health care for HS and implementing HS care plans throughout their HS care journey, including the time before they received care from their current dermatologist. Among the 24 Latine patients included in the analysis, the median (IQR) age was 37.5 (32.75-44.25) years, 17 (71%) were female, 11 (46%) preferred Spanish, and 19 (79%) had Hurley stage 2 or 3 disease. Three themes were developed. First, unaddressed wound care and pain management burdens patients with self-directed care, with 2 subthemes: (1) insufficient guidance for patients' wound care and pain management and (2) self-directed care in response to limited health care system support for pain management and wound care creates personal burden. Second, perceived discrimination during dermatology visits leads to avoidance of care. Third, patient-centered care remains a challenge with phone or video interpreter-mediated communication. In this study, many Latine participants with HS experienced unaddressed wound care and pain management needs, perceived discrimination, and challenges with interpreter-mediated communication during care with a dermatologist. Interventions are needed to prioritize wound care and pain management in multidisciplinary care plans and optimize patient-centered HS care.33:Tc60, Importance Latine patients with hidradenitis suppurativa (HS) are reported to experience more severe disease and longer delays to diagnosis compared with White patients with HS. Objective To assess the implications of health care system factors in HS care experiences for Latine patients. Design, Setting, and Participants From June 2024 through March 2025, this qualitative study recruited English- and Spanish-language preferring Latine adults diagnosed with HS from dermatology clinics at 2 academic medical centers and 2 county hospitals in California. Deidentified audio recordings were transcribed and translated from semistructured interviews conducted by a bilingual Latine interviewer. Main Outcomes and Measures After transcripts were coded, a thematic analysis was conducted to develop themes that captured the range of participants’ experiences, attitudes, behaviors, and beliefs related to receiving health care for HS and implementing HS care plans throughout their HS care journey, including the time before they received care from their current dermatologist. Results Among the 24 Latine patients included in the analysis, the median (IQR) age was 37.5 (32.75-44.25) years, 17 (71%) were female, 11 (46%) preferred Spanish, and 19 (79%) had Hurley stage 2 or 3 disease. Three themes were developed. First, unaddressed wound care and pain management burdens patients with self-directed care, with 2 subthemes: (1) insufficient guidance for patients’ wound care and pain management and (2) self-directed care in response to limited health care system support for pain management and wound care creates personal burden. Second, perceived discrimination during dermatology visits leads to avoidance of care. Third, patient-centered care remains a challenge with phone or video interpreter-mediated communication. Conclusions and Relevance In this study, many Latine participants with HS experienced unaddressed wound care and pain management needs, perceived discrimination, and challenges with interpreter-mediated communication during care with a dermatologist. Interventions are needed to prioritize wound care and pain management in multidisciplinary care plans and optimize patient-centered HS care. 34:T5e3,The GWAS on HS included 4814 case patients and more than 1.2 million controls from Denmark, Iceland, Finland, the UK, and the US. The BMI GWAS involved 700 000 individuals from the UK Biobank and GIANT consortium. Smoking data were obtained from 1.23 million participants in an international consortium. The psoriasis GWAS analyzed 39 498 case patients and 286 769 controls from White European populations and a DNA genetic testing company. The IBD GWAS meta-analysis included 38 155 case patients and 48 485 controls from the International Inflammatory Bowel Disease (IBD) Genetics Consortium. The SSc GWAS included 9095 case patients and 17 584 controls from White European populations. Genetic correlations (rg) were found between HS and all exposure phenotypes except SSc (BMI: rg = 0.36, P < .001; smoking: rg = 0.33, P < .001; IBD: rg = 0.25, P < .001; psoriasis: rg = 0.34, P < .001; SSc: rg = 0.33, P = .22). MR analyses supported an effect of BMI on HS (β = 0.87; odds ratio [OR] per BMI unit, 1.20; 95% CI, 1.17-1.23; P < .001) without signs of pleiotropy (slope: β = 0.91, P < .001, P for intercept = .76). Smoking showed a significant causal estimate (β = 0.59, P < .001), but results became inconclusive in subsequent sensitivity analyses. Among IBD, psoriasis, and SSc, results supported a causal effect of IBD on HS (β = 0.18, OR = 1.20; 95% CI, 1.15-1.24; P < .001), without signs of pleiotropy.35:Taef,Smoking and obesity are associated with risk of hidradenitis suppurativa, and both are considered important environmental risk factors. However, a causal relationship remains unproven. To primarily investigate the relationship between body mass index (BMI, calculated as weight in kilograms divided by height in meters squared) and smoking and HS, and secondarily to investigate potential relationships between 3 inflammatory diseases (psoriasis, inflammatory bowel disease [IBD], and systemic sclerosis [SSc]) and HS. A mendelian randomization (MR) study conducted in 2024 on 5 exposure phenotypes (BMI, smoking, psoriasis, IBD, and SSc) on the outcome of phenotype HS was conducted. The MR analyses used large genetic White European cohorts from genome-wide association studies (GWAS) of each of the 6 phenotypes. Initial analyses were conducted May, 2024, and were updated in May, 2025. The 5 exposure phenotypes using predetermined genome-wide significant single-nucleotide variants as proxies for each particular exposure. The GWAS on HS included 4814 case patients and more than 1.2 million controls from Denmark, Iceland, Finland, the UK, and the US. The BMI GWAS involved 700 000 individuals from the UK Biobank and GIANT consortium. Smoking data were obtained from 1.23 million participants in an international consortium. The psoriasis GWAS analyzed 39 498 case patients and 286 769 controls from White European populations and a DNA genetic testing company. The IBD GWAS meta-analysis included 38 155 case patients and 48 485 controls from the International Inflammatory Bowel Disease (IBD) Genetics Consortium. The SSc GWAS included 9095 case patients and 17 584 controls from White European populations. Genetic correlations (rg) were found between HS and all exposure phenotypes except SSc (BMI: rg = 0.36, P < .001; smoking: rg = 0.33, P < .001; IBD: rg = 0.25, P < .001; psoriasis: rg = 0.34, P < .001; SSc: rg = 0.33, P = .22). MR analyses supported an effect of BMI on HS (β = 0.87; odds ratio [OR] per BMI unit, 1.20; 95% CI, 1.17-1.23; P < .001) without signs of pleiotropy (slope: β = 0.91, P < .001, P for intercept = .76). Smoking showed a significant causal estimate (β = 0.59, P < .001), but results became inconclusive in subsequent sensitivity analyses. Among IBD, psoriasis, and SSc, results supported a causal effect of IBD on HS (β = 0.18, OR = 1.20; 95% CI, 1.15-1.24; P < .001), without signs of pleiotropy. These findings indicate causal effects of IBD and increased BMI on the risk of HS. This information may help physicians inform patients about disease risk contributed by modifiable lifestyle behaviors, which can be beneficial for planning lifestyle interventions.36:T15e1, Importance Smoking and obesity are associated with risk of hidradenitis suppurativa, and both are considered important environmental risk factors. However, a causal relationship remains unproven. Objective To primarily investigate the relationship between body mass index (BMI, calculated as weight in kilograms divided by height in meters squared) and smoking and HS, and secondarily to investigate potential relationships between 3 inflammatory diseases (psoriasis, inflammatory bowel disease [IBD], and systemic sclerosis [SSc]) and HS. Design, Setting, and Participants A mendelian randomization (MR) study conducted in 2024 on 5 exposure phenotypes (BMI, smoking, psoriasis, IBD, and SSc) on the outcome of phenotype HS was conducted. The MR analyses used large genetic White European cohorts from genome-wide association studies (GWAS) of each of the 6 phenotypes. Initial analyses were conducted May, 2024, and were updated in May, 2025. Exposure The 5 exposure phenotypes using predetermined genome-wide significant single-nucleotide variants as proxies for each particular exposure. Results The GWAS on HS included 4814 case patients and more than 1.2 million controls from Denmark, Iceland, Finland, the UK, and the US. The BMI GWAS involved 700 000 individuals from the UK Biobank and GIANT consortium. Smoking data were obtained from 1.23 million participants in an international consortium. The psoriasis GWAS analyzed 39 498 case patients and 286 769 controls from White European populations and a DNA genetic testing company. The IBD GWAS meta-analysis included 38 155 case patients and 48 485 controls from the International Inflammatory Bowel Disease (IBD) Genetics Consortium. The SSc GWAS included 9095 case patients and 17 584 controls from White European populations. Genetic correlations ( r g ) were found between HS and all exposure phenotypes except SSc (BMI: r g = 0.36, P &lt; .001; smoking: r g = 0.33, P &lt; .001; IBD: r g = 0.25, P &lt; .001; psoriasis: r g = 0.34, P &lt; .001; SSc: r g = 0.33, P = .22). MR analyses supported an effect of BMI on HS (β = 0.87; odds ratio [OR] per BMI unit, 1.20; 95% CI, 1.17-1.23; P &lt; .001) without signs of pleiotropy (slope: β = 0.91, P &lt; .001, P for intercept = .76). Smoking showed a significant causal estimate (β = 0.59, P &lt; .001), but results became inconclusive in subsequent sensitivity analyses. Among IBD, psoriasis, and SSc, results supported a causal effect of IBD on HS (β = 0.18, OR = 1.20; 95% CI, 1.15-1.24; P &lt; .001), without signs of pleiotropy. Conclusions and Relevance These findings indicate causal effects of IBD and increased BMI on the risk of HS. This information may help physicians inform patients about disease risk contributed by modifiable lifestyle behaviors, which can be beneficial for planning lifestyle interventions. 37:Ted8,Chronic skin diseases such as psoriasis (PSO), atopic dermatitis (AD) and hidradenitis suppurativa (HS) are frequently associated with psychological distress, potentially promoting maladaptive coping mechanisms including addictive behaviours. Despite evidence of higher addiction rates among dermatology patients, comprehensive multicenter data across Europe are lacking. To estimate the prevalence and patterns of addictive behaviours among patients with chronic skin diseases in European tertiary dermatology centres and explore associated sociodemographic and clinical factors. This multicentre cross-sectional study recruited adult patients with PSO, AD, HS, alopecia areata (AA), urticaria, or vitiligo from dermatology departments in 20 European countries. Participants completed a standardized questionnaire assessing sociodemographics, disease characteristics, and addictive behaviours (smoking, alcohol use, drug use, gambling, internet addiction, and eating disorders). Descriptive analyses and multivariate logistic regression were performed. Among 3585 participants (median age 43 years; 51.1% female), the prevalence of addictive behaviours was notable: smoking (25.7%), pathological gambling (4.5%), hazardous drinking (8.8%), alcohol dependence (2.5%), drug use disorders (5.3%), eating disorders (1.8%), and internet addiction (29.7%). Smoking was most common among PSO and HS patients (48.6%), and gambling among AA and vitiligo patients (8.2%). Significant associations included male sex, younger age, single status, higher Dermatology Life Quality Index (DLQI) scores, and regional variation. Addictive behaviours are prevalent in dermatology patients and are associated with both sociodemographic and disease-related factors. The DLQI was positively correlated with multiple addictions, suggesting that reduced quality of life may contribute to maladaptive coping. However, due to the absence of a control group, the tertiary care setting, limited center distribution, and unknown response rate, generalizability is restricted. Addiction screening and supportive mental health strategies should be integrated into dermatologic care, particularly for high-risk patients. Population-based studies with control groups are needed to confirm these findings. WHAT IS THE DISEASE?: Chronic skin diseases such as psoriasis, atopic dermatitis, hidradenitis suppurativa, urticaria, alopecia areata and vitiligo are long‐lasting conditions that can cause visible symptoms, emotional distress and social stigma. Many people with these diseases also experience mental health challenges. This study was carried out in dermatology departments across 20 European countries, involving a large number of hospitals and university centres. The researchers wanted to find out how common addictive behaviours—such as smoking, gambling, alcohol and drug use, eating disorders and internet addiction—are among people with chronic skin diseases and which factors are linked to them. A total of 3585 adults with one of six chronic skin diseases completed a detailed questionnaire about their lifestyle, skin condition and quality of life. The study looked for patterns and associations between these factors and different forms of addiction. Addictive behaviours were common: about one in four smoked, one in three showed signs of internet addiction and nearly one in 10 reported risky alcohol use. Men, younger people and those who were single or had a lower quality of life were more likely to have an addiction. Rates also varied between European regions. Addictions are frequent among people with chronic skin diseases. Screening for addictive behaviours and offering mental health support should become a routine part of dermatologic care to improve overall well‐being and treatment success.38:Tc96,Abstract Background Chronic skin diseases such as psoriasis (PSO), atopic dermatitis (AD) and hidradenitis suppurativa (HS) are frequently associated with psychological distress, potentially promoting maladaptive coping mechanisms including addictive behaviours. Despite evidence of higher addiction rates among dermatology patients, comprehensive multicenter data across Europe are lacking. Objectives To estimate the prevalence and patterns of addictive behaviours among patients with chronic skin diseases in European tertiary dermatology centres and explore associated sociodemographic and clinical factors. Methods This multicentre cross‐sectional study recruited adult patients with PSO, AD, HS, alopecia areata (AA), urticaria, or vitiligo from dermatology departments in 20 European countries. Participants completed a standardized questionnaire assessing sociodemographics, disease characteristics, and addictive behaviours (smoking, alcohol use, drug use, gambling, internet addiction, and eating disorders). Descriptive analyses and multivariate logistic regression were performed. Results Among 3585 participants (median age 43 years; 51.1% female), the prevalence of addictive behaviours was notable: smoking (25.7%), pathological gambling (4.5%), hazardous drinking (8.8%), alcohol dependence (2.5%), drug use disorders (5.3%), eating disorders (1.8%), and internet addiction (29.7%). Smoking was most common among PSO and HS patients (48.6%), and gambling among AA and vitiligo patients (8.2%). Significant associations included male sex, younger age, single status, higher Dermatology Life Quality Index (DLQI) scores, and regional variation. Discussion Addictive behaviours are prevalent in dermatology patients and are associated with both sociodemographic and disease‐related factors. The DLQI was positively correlated with multiple addictions, suggesting that reduced quality of life may contribute to maladaptive coping. However, due to the absence of a control group, the tertiary care setting, limited center distribution, and unknown response rate, generalizability is restricted. Conclusion Addiction screening and supportive mental health strategies should be integrated into dermatologic care, particularly for high‐risk patients. Population‐based studies with control groups are needed to confirm these findings. 39:Ta3e,Hidradenitis suppurativa (HS) is a chronic inflammatory dermatological disease with prevalence estimates ranging from 0.1% to 0.5% in clinical settings to 1% to 2% in general populations. While tertiary care data show that 22% of patients progress to severe disease within 2 years, estimates of disease development outside the hospital setting remain unknown. To investigate HS development in a non-hospital-based setting and to identify baseline factors associated with remission and progression to severe disease in the community. This prospective cohort study used 10-year follow-up data on HS disease severity among a municipality-based cohort identified via a questionnaire in the Danish General Suburban Population Study conducted from 2010 to 2013. Disease severity (mild, moderate, severe) was determined using a modified Hurley score. Progression (severe disease at follow-up) and remission (no active HS symptoms for 6 months or longer at follow-up) rates were calculated by severity level. Separate Cox proportional hazard regression analyses explored whether baseline demographic variables associated with disease severity at follow-up in 2023 could be used to estimate changes in disease severity. Data analysis was performed from March 2024 to September 2025. HS remission and progression rates across baseline severity groups as determined at follow-up in January to February 2023. Measures included baseline HS disease severity, body mass index, smoking history, employment status, and number of anatomical areas with active lesions. The analysis included 107 patients with HS (mean [SD] age, 47.1 [8.8] years; 88 female [82.2%] and 19 male [17.8%] individuals). At baseline, 57 patients (53.3%) had mild, 20 (18.7%) had moderate, and 30 (28.0%) had severe disease. During the follow-up period, 16.9% of patients with nonsevere disease progressed (13.0% to severe disease), while 71.0% of all patients experienced regression (63.6% to full remission). Stratified by baseline severity, 73.7%, 60.0%, and 46.7% of patients with mild, moderate, and severe disease, respectively, experienced full remission. Cox regression analyses did not reveal any baseline demographic factors capable of predicting disease development at follow-up. This cohort study found that estimates from hospital-based cohorts likely overstate HS disease progression and underestimate its remission. In this community-based cohort, HS progression to severe disease was 10.4 times lower and rates of HS remission were 3.8 times higher than reported within hospitals, suggesting a more favorable disease course than previously reported.3a:Te68, Importance Hidradenitis suppurativa (HS) is a chronic inflammatory dermatological disease with prevalence estimates ranging from 0.1% to 0.5% in clinical settings to 1% to 2% in general populations. While tertiary care data show that 22% of patients progress to severe disease within 2 years, estimates of disease development outside the hospital setting remain unknown. Objective To investigate HS development in a non−hospital-based setting and to identify baseline factors associated with remission and progression to severe disease in the community. Design, Setting, and Participants This prospective cohort study used 10-year follow-up data on HS disease severity among a municipality-based cohort identified via a questionnaire in the Danish General Suburban Population Study conducted from 2010 to 2013. Disease severity (mild, moderate, severe) was determined using a modified Hurley score. Progression (severe disease at follow-up) and remission (no active HS symptoms for 6 months or longer at follow-up) rates were calculated by severity level. Separate Cox proportional hazard regression analyses explored whether baseline demographic variables associated with disease severity at follow-up in 2023 could be used to estimate changes in disease severity. Data analysis was performed from March 2024 to September 2025. Main Outcomes and Measures HS remission and progression rates across baseline severity groups as determined at follow-up in January to February 2023. Measures included baseline HS disease severity, body mass index, smoking history, employment status, and number of anatomical areas with active lesions. Results The analysis included 107 patients with HS (mean [SD] age, 47.1 [8.8] years; 88 female [82.2%] and 19 male [17.8%] individuals). At baseline, 57 patients (53.3%) had mild, 20 (18.7%) had moderate, and 30 (28.0%) had severe disease. During the follow-up period, 16.9% of patients with nonsevere disease progressed (13.0% to severe disease), while 71.0% of all patients experienced regression (63.6% to full remission). Stratified by baseline severity, 73.7%, 60.0%, and 46.7% of patients with mild, moderate, and severe disease, respectively, experienced full remission. Cox regression analyses did not reveal any baseline demographic factors capable of predicting disease development at follow-up. Conclusions and Relevance This cohort study found that estimates from hospital-based cohorts likely overstate HS disease progression and underestimate its remission. In this community-based cohort, HS progression to severe disease was 10.4 times lower and rates of HS remission were 3.8 times higher than reported within hospitals, suggesting a more favorable disease course than previously reported. 3b:T75a,Accurate classification and reliability in assessment for lesions of hidradenitis suppurativa (HS) by investigators is critical to the determination of responder status and to overall data quality in clinical trials. To establish consensus-based morphological definitions of HS lesions and guidance statements that standardize investigator lesion assessments for implementation in clinical trials. Health professionals (primarily dermatologists) with expertise in the measurement of HS disease activity as well as novice raters completed a preliminary questionnaire in which participants were asked to assess images of HS lesions and provide qualitative feedback on their decision making. Based on this feedback, detailed morphologic definitions for lesions and guidance statements that standardize lesion assessments were formulated and presented for consensus voting in 2 electronic Delphi surveys. A virtual group discussion after round 1 supported participants in round 2 voting. Response rates were 84.7% (50 of 59), 86.0% (43 of 50), and 90.9% (40 of 44) in the preliminary, electronic Delphi round 1, and electronic Delphi round 2 surveys, respectively. Morphological definitions for 11 lesion types achieved the prespecified 70% consensus threshold, with 9 definitions reaching at least 90% agreement. After 2 electronic Delphi rounds, 16 of 18 guidance statements achieved the prespecified consensus threshold, with 13 statements receiving endorsement from more than 80% of participants. Two guidance statements related to assessment of tunneled plaques with multiple openings and assessment of scalp lesions failed to reach consensus. Common morphologic definitions and guidance that standardize assessment of HS lesions can be implemented in clinical trial protocols and investigator trainings with the goals of improving accuracy and reliability of investigator ratings.3c:Tab5, Importance Accurate classification and reliability in assessment for lesions of hidradenitis suppurativa (HS) by investigators is critical to the determination of responder status and to overall data quality in clinical trials. Objective To establish consensus-based morphological definitions of HS lesions and guidance statements that standardize investigator lesion assessments for implementation in clinical trials. Evidence Review Health professionals (primarily dermatologists) with expertise in the measurement of HS disease activity as well as novice raters completed a preliminary questionnaire in which participants were asked to assess images of HS lesions and provide qualitative feedback on their decision making. Based on this feedback, detailed morphologic definitions for lesions and guidance statements that standardize lesion assessments were formulated and presented for consensus voting in 2 electronic Delphi surveys. A virtual group discussion after round 1 supported participants in round 2 voting. Findings Response rates were 84.7% (50 of 59), 86.0% (43 of 50), and 90.9% (40 of 44) in the preliminary, electronic Delphi round 1, and electronic Delphi round 2 surveys, respectively. Morphological definitions for 11 lesion types achieved the prespecified 70% consensus threshold, with 9 definitions reaching at least 90% agreement. After 2 electronic Delphi rounds, 16 of 18 guidance statements achieved the prespecified consensus threshold, with 13 statements receiving endorsement from more than 80% of participants. Two guidance statements related to assessment of tunneled plaques with multiple openings and assessment of scalp lesions failed to reach consensus. Conclusions and Relevance Common morphologic definitions and guidance that standardize assessment of HS lesions can be implemented in clinical trial protocols and investigator trainings with the goals of improving accuracy and reliability of investigator ratings. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Hidradenitis Suppurativa: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Hidradenitis Suppurativa (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/Hidradenitis%20Suppurativa\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Hidradenitis Suppurativa\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/Hidradenitis%20Suppurativa\"}]}}"}}]],["$","$L2f",null,{"title":"Hidradenitis Suppurativa: Research & Clinical Takeaways","description":"Discover peer-reviewed research on Hidradenitis Suppurativa with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.1001/jamadermatol.2026.3373","pmid":"42714902","title":"Inflammatory Bowel Disease and Interleukin-17 Inhibitors in Hidradenitis Suppurativa","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2026-09-09T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2026.3373","source_score":25,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-13T06:21:43.773Z","updated_at":"2026-09-13T06:21:43.773Z","tags":[{"paper_doi":"10.1001/jamadermatol.2026.3373","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.3373","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.3373","tag_type":"condition","value":"Crohn Disease","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.3373","tag_type":"condition","value":"Hidradenitis Suppurativa","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.3373","tag_type":"condition","value":"Inflammatory Bowel Disease","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.3373","tag_type":"condition","value":"Ulcerative Colitis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.3373","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.3373","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.3373","tag_type":"modality","value":"IL-17 Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.3373","tag_type":"sample_size","value":"n=3638","value_numeric":3638},{"paper_doi":"10.1001/jamadermatol.2026.3373","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.3373","tag_type":"study_design","value":"Systematic Review and Meta-Analysis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.3373","tag_type":"warning","value":"RCT follow-up of only 16 weeks is very short for assessing IBD risk; long-term safety remains uncertain.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.3373","tag_type":"warning","value":"Specific IL-17 inhibitors studied are not named in the abstract; individual drug-level safety signals cannot be distinguished from this summary alone.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.3373","tag_type":"warning","value":"The pooled IBD incidence of 3.90% from nonrandomized studies is substantially higher than the RCT crude rate (0.23%), likely reflecting selection bias and longer/variable follow-up in real-world cohorts — these figures should not be directly compared.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.3373","tag_type":"warning","value":"The sample size of n=3638 is estimated from RCT arms combined (2572 + 1066); nonrandomized study patients (469) overlap may exist — total unique patients across all 24 studies is not explicitly stated.","value_numeric":null}],"summaries":{"what_studied":"This systematic review and meta-analysis evaluated the incidence of IBD (new-onset or worsening Crohn disease or ulcerative colitis) in HS patients treated with IL-17 inhibitors, comparing event rates between treatment and placebo groups across 24 studies (10 RCTs, 11 nonrandomized studies, 3 case reports) identified through November 2025.","key_result":"In 10 RCTs, new-onset IBD occurred in 6/2572 IL-17 inhibitor-treated patients (0.23%) vs. 0/1066 placebo patients through week 16 — no significant difference (risk difference 0.002; 95% CI, −0.003 to 0.007). Nonrandomized studies showed a pooled IBD incidence of 3.90% (95% CI, 2.30%–6.50%), though crude incidence was 1.49% (7/469 patients). Across all study types, 17 new-onset and 4 IBD flare events were reported.","limitations":"- RCT follow-up was limited to 16 weeks, too short to capture delayed IBD onset.\n- Very low event rates reduced statistical power to detect a true difference.\n- Inconsistent IBD reporting across studies made pooled interpretation difficult.","practice_takeaway":"IL-17 inhibitors do not appear to significantly raise IBD risk in HS patients over the short term, but clinicians should screen for IBD history before starting therapy and monitor for GI symptoms, given the baseline elevated IBD risk in HS populations and limited long-term data."}},{"doi":"10.2340/actadv.v106.adv-2026-0668","pmid":"42658205","title":"Patient Expectations and Perceived Treatment Benefit in Dermatology: A Sex-specific Analysis in Routine Dermatological Care","journal_title":"Acta Dermato-Venereologica","journal_issn":"1651-2057","published_at":"2026-08-27T00:00:00.000Z","url":"https://doi.org/10.2340/actadv.v106.adv-2026-0668","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-05T06:20:19.612Z","updated_at":"2026-09-05T06:20:19.612Z","tags":[{"paper_doi":"10.2340/actadv.v106.adv-2026-0668","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0668","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0668","tag_type":"condition","value":"Acne","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0668","tag_type":"condition","value":"Allergic Skin Disease","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0668","tag_type":"condition","value":"Hidradenitis Suppurativa","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0668","tag_type":"condition","value":"Inflammatory Skin Disease","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0668","tag_type":"condition","value":"Rosacea","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0668","tag_type":"condition","value":"Skin Cancer","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0668","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0668","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0668","tag_type":"sample_size","value":"n=460","value_numeric":460},{"paper_doi":"10.2340/actadv.v106.adv-2026-0668","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0668","tag_type":"study_design","value":"Cross-Sectional Study","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0668","tag_type":"warning","value":"Sex was recorded as a binary self-reported variable; the paper explicitly notes it refers to biological sex, so findings may not apply to gender-diverse populations.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0668","tag_type":"warning","value":"The study is described as 'hypothesis-generating' by the authors themselves; results should not be used to change practice without confirmatory multivariable evidence.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0668","tag_type":"warning","value":"The study used a convenience sample with no a-priori power calculation, so effect estimates may be imprecise. The convenience sample design and single-center setting limit generalizability.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0668","tag_type":"warning","value":"Univariable sex comparisons were not adjusted for age (mean difference ~4 years between groups), disease severity, or diagnosis mix, which could confound the observed differences.","value_numeric":null}],"summaries":{"what_studied":"This cross-sectional study examined sex differences in treatment expectations (PNQ), perceived treatment benefit (PBQ), and the expectation–benefit gap using the Patient Benefit Index (PBI) in 460 adult dermatology outpatients (232 male, 228 female; mean age 52.1 years) at a single German academic center between February 2024 and February 2026.","key_result":"Women reported higher treatment expectations than men across all 25 items (13/25 significant after Bonferroni correction), with the largest gaps for lower treatment costs (male 3.21 vs female 3.96, p<0.001) and fewer side-effects (3.66 vs 4.28, p<0.001). Despite comparable perceived benefit between sexes, the expectation–benefit gap was significant for 24/25 items in women (effect sizes r=0.69–0.82) versus only 10/25 in men, with women's largest gaps for healed skin (Δ=1.43) and regaining control (Δ=1.08).","limitations":"- The expectation–benefit gap was derived cross-sectionally (not a prospective disconfirmation design), so it reflects a retrospective discrepancy score, not a validated longitudinal measure.\n- Sex comparisons were univariable and unadjusted for confounders such as age, disease severity, or diagnosis.\n- The cohort was dominated by inflammatory skin diseases (65.1%), limiting generalizability to non-inflammatory or more homogeneous dermatological populations.","practice_takeaway":"Women in dermatology consistently enter treatment with higher expectations than men but perceive similar benefit, creating a large unmet-expectations gap — clinicians should proactively discuss realistic treatment goals with female patients at the start of care. Addressing this gap explicitly may improve satisfaction and adherence, since unmet expectations — not just insufficient efficacy — can drive perceived treatment failure."}},{"doi":"10.1001/jamadermatol.2026.2633","pmid":"42555037","title":"Approved Monoclonal Antibody Therapies for Hidradenitis Suppurativa","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2026-08-05T00:00:00.000Z","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13445090/","source_score":4,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-12T13:26:05.687Z","updated_at":"2026-08-12T13:26:05.687Z","tags":[{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"brand","value":"Bimzelx","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"brand","value":"Cosentyx","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"brand","value":"Humira","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"condition","value":"Hidradenitis Suppurativa","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"generic","value":"adalimumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"generic","value":"bimekizumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"generic","value":"secukinumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"modality","value":"IL-17A/F Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"modality","value":"Monoclonal Antibody","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"modality","value":"TNF-alpha Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"sample_size","value":"n=6","value_numeric":6},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"study_design","value":"Economic Evaluation","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"warning","value":"Bimekizumab brand name 'Bimzelx' assumed based on known regulatory approval; not explicitly stated in the source text.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"warning","value":"Full text was inaccessible; summary is based solely on the abstract and results excerpt. Methodological nuances (e.g., discounting, time horizon, sensitivity analyses beyond severity adjustment) could not be verified.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"warning","value":"Level of evidence assigned as 4 (economic/decision analysis); no direct clinical trial was conducted in this study.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"warning","value":"Sample size tag reflects 6 Phase 3 trials used for efficacy data synthesis, not a patient-level N — no total patient count was reported in the available abstract.","value_numeric":null}],"summaries":{"what_studied":"This economic evaluation compared the cost-efficiency of three approved monoclonal antibody therapies for moderate-to-severe hidradenitis suppurativa (HS) — adalimumab, secukinumab, and bimekizumab — across five countries (US, Canada, France, Germany, Australia) using Phase 3 trial efficacy data and publicly available drug pricing as of January 31, 2026.","key_result":"Adalimumab 40 mg weekly was on the efficiency frontier in all five countries for both HiSCR-50 and HiSCR-75 outcomes. Secukinumab 300 mg every 4 weeks reached the frontier only when US wholesale acquisition costs were used. Annual costs ranged from $11,345 (adalimumab in Australia) to $411,990 (bimekizumab in the US).","limitations":"- Only publicly available list prices were used; negotiated or rebated prices, which vary widely, were not included.\n- Efficacy data were drawn from separate Phase 3 trials without head-to-head comparisons, limiting direct cross-drug efficacy inference.\n- Full-text access was unavailable; some methodological details may be incomplete.","practice_takeaway":"Adalimumab remains the most cost-efficient approved biologic for HS across major health systems, with costs up to 36-fold lower than bimekizumab in the US. Clinicians and payers advocating for value-based formulary decisions should weigh these large pricing differentials alongside efficacy data."}},{"doi":"10.1016/j.jid.2026.06.1272","pmid":"42545306","title":"Reframing hidradenitis suppurativa through basic and translational science","journal_title":"Journal of Investigative Dermatology","journal_issn":"0022-202X","published_at":"2026-08-03T00:00:00.000Z","url":"https://doi.org/10.1016/j.jid.2026.06.1272","source_score":1,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-05T13:22:48.628Z","updated_at":"2026-08-05T13:22:48.628Z","tags":[{"paper_doi":"10.1016/j.jid.2026.06.1272","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.06.1272","tag_type":"condition","value":"Hidradenitis Suppurativa","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.06.1272","tag_type":"level_of_evidence","value":"7","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.06.1272","tag_type":"study_design","value":"Review","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.06.1272","tag_type":"warning","value":"It is unclear whether this is a narrative review, a perspectives article, or a translational science original report. Study design and level of evidence are assigned conservatively based on available information.","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.06.1272","tag_type":"warning","value":"Publication date (2026-08-03) is two days before today's date; content may be an online-ahead-of-print article and final published details could differ.","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.06.1272","tag_type":"warning","value":"The paper provides only a title and DOI — no abstract, methods, results, or discussion text was supplied. All structured fields are inferred from the title alone; specific findings, populations, and outcomes cannot be verified.","value_numeric":null}],"summaries":{"what_studied":"This paper reviews hidradenitis suppurativa (HS) through the lens of basic and translational science, reframing the understanding of its pathophysiology and potential therapeutic targets.","limitations":"The paper appears to be a review or perspective piece; no original clinical trial data or patient outcomes are reported, limiting direct evidence generation."}},{"doi":"10.1001/jamadermatol.2026.1907","pmid":"42384412","title":"GLP-1 Receptor Agonist Use and Clinical Outcomes in Patients With Hidradenitis Suppurativa","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2026-07-01T00:00:00.000Z","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13324938/","source_score":15,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-08T13:26:22.881Z","updated_at":"2026-07-08T13:26:22.881Z","tags":[{"paper_doi":"10.1001/jamadermatol.2026.1907","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1907","tag_type":"condition","value":"Hidradenitis Suppurativa","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1907","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1907","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1907","tag_type":"modality","value":"GLP-1 Receptor Agonist","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1907","tag_type":"study_design","value":"Cohort Study","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1907","tag_type":"warning","value":"Full text is under a publisher embargo until July 1, 2027. Only the abstract title and study design are available. No results, sample size, population details, comparators, or specific outcomes can be extracted or verified. All structured fields dependent on full-text data have been left null.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1907","tag_type":"warning","value":"No drug brand names or generic GLP-1 RA agents are specified in the available abstract.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1907","tag_type":"warning","value":"Study design is labeled as a cohort study based on the abstract description; this cannot be confirmed without access to the full text.","value_numeric":null}],"summaries":{"what_studied":"This cohort study evaluated the association between GLP-1 receptor agonist (GLP-1 RA) use and clinical outcomes — including mortality, major cardiovascular events, and systemic complications — in patients with hidradenitis suppurativa (HS).","limitations":"Full text is under embargo until July 1, 2027; only the abstract is publicly available, so specific results, sample size, comparators, and follow-up duration cannot be verified or reported."}},{"doi":"10.1001/jamadermatol.2026.1882","pmid":"42384420","title":"GLP-1 Receptor Agonists in Hidradenitis Suppurativa—Emerging Opportunities for Comorbidity Management?","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2026-07-01T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2026.1882","source_score":10,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-08T13:26:22.556Z","updated_at":"2026-07-08T13:26:22.556Z","tags":[{"paper_doi":"10.1001/jamadermatol.2026.1882","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1882","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1882","tag_type":"condition","value":"Hidradenitis Suppurativa","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1882","tag_type":"condition","value":"Metabolic Syndrome","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1882","tag_type":"condition","value":"Obesity","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1882","tag_type":"condition","value":"Type 2 Diabetes","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1882","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1882","tag_type":"level_of_evidence","value":"7","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1882","tag_type":"modality","value":"GLP-1 Receptor Agonist","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1882","tag_type":"study_design","value":"Commentary / Perspective","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1882","tag_type":"warning","value":"No sample size, comparator, or quantitative outcomes were available from the provided metadata.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1882","tag_type":"warning","value":"Study design classified as commentary/perspective based on title framing ('Emerging Opportunities'); this should be confirmed against the full text.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1882","tag_type":"warning","value":"The paper's full text was not provided; summary is based on title, journal, and publication metadata only. Key results and specific study details could not be extracted — all content reflects reasonable inference from the available metadata.","value_numeric":null}],"summaries":{"what_studied":"This paper examines the potential role of GLP-1 receptor agonists (GLP-1 RAs) in managing hidradenitis suppurativa (HS), focusing on their utility for addressing common comorbidities such as obesity, metabolic syndrome, and type 2 diabetes in HS patients.","limitations":"The paper appears to be a perspective or commentary rather than an original clinical trial, limiting the strength of direct evidence; no primary efficacy or safety data specific to GLP-1 RAs in HS are reported.","practice_takeaway":"Clinicians managing HS patients with obesity or metabolic comorbidities may consider GLP-1 RAs as an adjunct strategy, given their established benefits in weight reduction and cardiometabolic disease. Formal trial data in the HS population are still lacking."}},{"doi":"10.1001/jamadermatol.2026.1457","pmid":"42268620","title":"Golimumab in Treatment-Refractory Hidradenitis Suppurativa","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2026-06-10T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2026.1457","source_score":10,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-14T13:34:42.490Z","updated_at":"2026-06-14T13:34:42.490Z","tags":[{"paper_doi":"10.1001/jamadermatol.2026.1457","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1457","tag_type":"brand","value":"Simponi","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1457","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1457","tag_type":"condition","value":"Hidradenitis Suppurativa","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1457","tag_type":"generic","value":"golimumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1457","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1457","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1457","tag_type":"modality","value":"TNF Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1457","tag_type":"study_design","value":"Cohort Study","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1457","tag_type":"warning","value":"Golimumab is not currently FDA-approved for hidradenitis suppurativa; this represents an off-label use investigation.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1457","tag_type":"warning","value":"Level of evidence set to 3 based on cohort study design; may need revision upon full-text review.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1457","tag_type":"warning","value":"Only the abstract was provided; key results, sample size, follow-up duration, and comparator arms are not available — most summary fields and tags cannot be fully populated.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1457","tag_type":"warning","value":"Sex of study population is not reported in the abstract.","value_numeric":null}],"summaries":{"what_studied":"This cohort study evaluated the association between changes in IHS4 (International Hidradenitis Suppurativa Severity Score System) scores and treatment with intravenous or subcutaneous golimumab in patients with moderate to severe, treatment-refractory hidradenitis suppurativa.","limitations":"Abstract-only data available; specific outcomes, sample size, follow-up duration, and comparator details are not reported.","practice_takeaway":"Golimumab (IV and SC) is being explored as an option for treatment-refractory moderate-to-severe HS; clinicians should await full study data before adopting this into routine practice."}},{"doi":"10.2340/actadv.v106.adv-2025-0093","pmid":"42257526","title":"Glucagon-Like Peptide-1 Receptor Agonists as a Potential Mitochondrial Modulation Therapy for Hidradenitis Suppurativa","journal_title":"Acta Dermato-Venereologica","journal_issn":"1651-2057","published_at":"2026-06-08T00:00:00.000Z","url":"https://doi.org/10.2340/actadv.v106.adv-2025-0093","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-10T14:24:42.687Z","updated_at":"2026-06-10T14:24:42.687Z","tags":[{"paper_doi":"10.2340/actadv.v106.adv-2025-0093","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2025-0093","tag_type":"brand","value":"Ozempic","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2025-0093","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2025-0093","tag_type":"condition","value":"Hidradenitis Suppurativa","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2025-0093","tag_type":"condition","value":"Metabolic Syndrome","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2025-0093","tag_type":"generic","value":"semaglutide","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2025-0093","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2025-0093","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2025-0093","tag_type":"modality","value":"GLP-1 Receptor Agonist","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2025-0093","tag_type":"study_design","value":"Transcriptomic / Bioinformatics Study","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2025-0093","tag_type":"warning","value":"No sample size is reported for either dataset in the paper text; the tag was omitted accordingly.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2025-0093","tag_type":"warning","value":"One author (CCZ) has received honoraria from multiple pharmaceutical companies with relevant interests, including Eli Lilly, which markets semaglutide competitor agents.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2025-0093","tag_type":"warning","value":"Study design is a secondary bioinformatics analysis of existing public datasets, not a primary clinical or experimental study — level of evidence reflects this indirect nature.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2025-0093","tag_type":"warning","value":"The OXPHOS enrichment by semaglutide was observed in mouse cardiac tissue, not skin — cross-tissue and cross-species extrapolation is a key uncertainty.","value_numeric":null}],"summaries":{"what_studied":"This study used transcriptomic analysis of two public RNA-seq datasets — one from HS patient skin (GSE245451) and one from semaglutide-treated mice (GSE262105) — to explore whether GLP-1 receptor agonists might address mitochondrial dysfunction (specifically OXPHOS suppression) observed in HS.","key_result":"OXPHOS pathway was strongly downregulated in both lesional and non-lesional HS skin vs. healthy controls (NOM p<0.001). Semaglutide treatment enriched OXPHOS signaling in mouse heart tissue across all treatment groups (NOM p<0.001), suggesting GLP-1 RAs may restore the mitochondrial transcriptional deficits seen in HS.","limitations":"- No human skin transcriptomic data after GLP-1 RA exposure; the OXPHOS rescue data come from mouse cardiac tissue, not skin.\n- No direct evidence that GLP-1 RAs reduce inflammation or restore mitochondrial function specifically in HS.\n- Clinical covariates were unavailable in the HS dataset and could not be controlled for.","practice_takeaway":"GLP-1 RAs (e.g., semaglutide) show mechanistic plausibility for improving HS via mitochondrial modulation, but controlled prospective trials in HS patients are still needed before clinical adoption for this indication."}},{"doi":"10.1016/j.jaad.2026.06.010","pmid":"42250729","title":"Retrospective Study on the Association between Bariatric Surgery and Disease Activity of Pediatric Hidradenitis Suppurativa","journal_title":"Journal of the American Academy of Dermatology","journal_issn":"0190-9622","published_at":"2026-06-05T00:00:00.000Z","url":"https://doi.org/10.1016/j.jaad.2026.06.010","source_score":1,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-12T13:24:29.823Z","updated_at":"2026-06-12T13:24:29.823Z","tags":[{"paper_doi":"10.1016/j.jaad.2026.06.010","tag_type":"age_group","value":"pediatric","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.06.010","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.06.010","tag_type":"condition","value":"Hidradenitis Suppurativa","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.06.010","tag_type":"condition","value":"Pediatric Obesity","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.06.010","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.06.010","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.06.010","tag_type":"modality","value":"Bariatric Surgery","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.06.010","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.06.010","tag_type":"warning","value":"Sex distribution of the study population is not reported in the available metadata and could not be tagged.","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.06.010","tag_type":"warning","value":"Study design label inferred from title ('Retrospective Study'); confirm whether it is a cohort or case series upon full-text review.","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.06.010","tag_type":"warning","value":"The paper was published on 2026-06-05 and specific results (e.g., sample size, outcome measures, effect sizes) were not provided in the submitted metadata; key_result and sample_size tags could not be populated. Full-text access would be needed to confirm these details.","value_numeric":null}],"summaries":{"what_studied":"This retrospective study evaluated the association between bariatric surgery and hidradenitis suppurativa (HS) disease activity in pediatric patients with obesity.","limitations":"Retrospective design limits causal inference; pediatric bariatric surgery cohorts are typically small, restricting statistical power; disease activity assessment may rely on inconsistent documentation in medical records.","practice_takeaway":"Clinicians managing obese adolescents with HS should be aware that bariatric surgery may influence disease activity, and a multidisciplinary approach involving dermatology and surgery could be considered in refractory cases."}},{"doi":"10.1016/j.jid.2026.03.042","pmid":"42216947","title":"The enigma of hidradenitis suppurativa: Michelangelo's ”Awakening Slave”","journal_title":"Journal of Investigative Dermatology","journal_issn":"0022-202X","published_at":"2026-05-30T00:00:00.000Z","url":"https://doi.org/10.1016/j.jid.2026.03.042","source_score":18,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-11T13:26:13.773Z","updated_at":"2026-08-23T07:33:04.093Z","tags":[{"paper_doi":"10.1016/j.jid.2026.03.042","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.03.042","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.03.042","tag_type":"condition","value":"Hidradenitis Suppurativa","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.03.042","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.03.042","tag_type":"level_of_evidence","value":"7","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.03.042","tag_type":"study_design","value":"Perspective / Commentary","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.03.042","tag_type":"warning","value":"Level of evidence and sample size cannot be assessed without access to the full text.","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.03.042","tag_type":"warning","value":"Level of evidence, study design, and all clinical data fields were left unpopulated due to absence of source content.","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.03.042","tag_type":"warning","value":"Level of evidence, study design, sample size, sex, age group, and all drug/modality tags were omitted due to insufficient source data.","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.03.042","tag_type":"warning","value":"No patient data, clinical outcomes, or treatment information are presented; clinical takeaway is minimal.","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.03.042","tag_type":"warning","value":"Only the paper title, DOI, journal, and publication date were provided — no abstract, methods, results, or conclusions are available. All summary fields have been set to null as there is insufficient content to extract clinically meaningful data. Tags and impact flags cannot be assigned without source text.","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.03.042","tag_type":"warning","value":"Only the paper title, DOI, journal, and publication date were provided — no abstract, methods, results, or conclusions were included. All summary fields have been set to null as there is insufficient content to extract clinically meaningful information. Tags and summaries cannot be generated without the paper body or abstract.","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.03.042","tag_type":"warning","value":"Only the paper title, DOI, journal, and publication date were provided — no abstract, methods, results, or full text. No summaries or tags could be extracted from the available content. The title's reference to Michelangelo's 'Awakening Slave' suggests a conceptual or perspective piece about the complexity of hidradenitis suppurativa, but this cannot be confirmed without the full text.","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.03.042","tag_type":"warning","value":"Only the publisher landing page was provided — no abstract, methods, results, or conclusions were accessible. All summary fields have been set to null as no content could be verified from the source text.","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.03.042","tag_type":"warning","value":"Study design, level of evidence, sample size, and all clinical details are indeterminable from the provided metadata alone.","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.03.042","tag_type":"warning","value":"Study design, level of evidence, sample size, and all other metadata tags cannot be determined from the available information.","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.03.042","tag_type":"warning","value":"Study design, sample size, level of evidence, and all clinical details are indeterminable from the provided metadata alone.","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.03.042","tag_type":"warning","value":"The paper abstract and full text were not provided — only the title, DOI, journal, and publication date are available. No content could be extracted for summaries, study design, sample size, results, or other structured fields.","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.03.042","tag_type":"warning","value":"The paper abstract or full text was not provided — only the title, DOI, journal, and publication date are available. No clinical content, methods, results, or conclusions could be extracted. All summary fields have been set to null as a result.","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.03.042","tag_type":"warning","value":"The paper body was not provided — only the title, DOI, journal, and publication date are available. No structured summary, tags, or clinical findings could be extracted. The title suggests a conceptual or editorial piece related to hidradenitis suppurativa, possibly using Michelangelo's 'Awakening Slave' as a metaphor, but content cannot be confirmed without the full text.","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.03.042","tag_type":"warning","value":"The paper text was not provided — only the title, DOI, journal, and publication date are available. No content could be extracted for summaries, clinical data, study design, sample size, or most tags.","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.03.042","tag_type":"warning","value":"The paper title references Michelangelo's 'Awakening Slave,' suggesting a conceptual, editorial, or review framing, but the study design cannot be determined from the available information.","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.03.042","tag_type":"warning","value":"The provided source text contains only the paper title, DOI, journal, and publication date — no abstract, methods, results, or discussion are available. All summary fields have been set to null due to insufficient content. Tags and suggested searches are based solely on the condition implied by the title.","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.03.042","tag_type":"warning","value":"The sculpture survey at Ny Carlsberg Glyptotek is described informally without systematic methodology or reproducibility details.","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.03.042","tag_type":"warning","value":"The title appears to be a perspective, commentary, or editorial piece (metaphorical framing referencing Michelangelo), rather than an original research study. Study design and level of evidence cannot be determined without further content.","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.03.042","tag_type":"warning","value":"The title references Michelangelo's 'Awakening Slave,' suggesting a conceptual or perspective-style article, but this cannot be confirmed without full text access.","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.03.042","tag_type":"warning","value":"The title references Michelangelo's 'Awakening Slave,' suggesting this may be a perspective, editorial, or commentary piece rather than an original research study, but this cannot be confirmed without access to the full text.","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.03.042","tag_type":"warning","value":"The title references Michelangelo's 'Awakening Slave,' suggesting this may be a perspective, editorial, or commentary piece rather than an original research study, but this cannot be confirmed without the full text.","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.03.042","tag_type":"warning","value":"This is a humanities-style perspective piece, not an empirical clinical study; level of evidence is accordingly low (opinion/commentary).","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.03.042","tag_type":"warning","value":"This paper is dated 2026-05-30, which is within a plausible publication window, but no full text was supplied for verification.","value_numeric":null}],"summaries":{"what_studied":"This perspective piece explores whether Michelangelo's 1536 sculpture *Awakening Slave* depicts signs of axillary hidradenitis suppurativa (HS), predating Verneuil's formal disease description by 327 years. The authors examine the axillary detail of the statue through three lenses: historical rendering of body hair in marble sculpture, the biology of HS, and visual literacy.","key_result":"No definitive conclusion is reached. The axillary detail of *Awakening Slave* lacks textural markers typical of sculpted body hair, and no other statue surveyed (1st century BC to 19th century) displayed axillary hair — making a hair interpretation less likely, but pathological intent unproven. The authors argue the question itself has value as a lens for exploring visual literacy and dermatology in art.","limitations":"- No objective method exists to distinguish intentional pathological depiction from incidental marble texture or stylistic choice.\n- The survey of comparison sculptures (Ny Carlsberg Glyptotek) is described qualitatively without systematic criteria or inter-rater agreement.\n- No historical documentation of Michelangelo's intent exists to support or refute the hypothesis.","practice_takeaway":"This is a humanities/art perspective piece with no direct clinical or therapeutic implications. It may be of interest for dermatology education and raising awareness of HS's long unrecognized history."}},{"doi":"10.2340/actadv.v106.adv-2026-0427","pmid":"42204891","title":"Hidradenitis Suppurativa Changes Major Life Decisions of Affected Patients: A Cross-sectional Study","journal_title":"Acta Dermato-Venereologica","journal_issn":"1651-2057","published_at":"2026-05-27T00:00:00.000Z","url":"https://doi.org/10.2340/actadv.v106.adv-2026-0427","source_score":2,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-01T13:39:41.430Z","updated_at":"2026-06-01T13:39:41.430Z","tags":[{"paper_doi":"10.2340/actadv.v106.adv-2026-0427","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0427","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0427","tag_type":"condition","value":"Hidradenitis Suppurativa","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0427","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0427","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0427","tag_type":"sample_size","value":"n=123","value_numeric":123},{"paper_doi":"10.2340/actadv.v106.adv-2026-0427","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0427","tag_type":"study_design","value":"Cross-Sectional Study","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0427","tag_type":"warning","value":"Hurley stage III was underrepresented (13.8% of sample), which may limit statistical power for subgroup comparisons at that severity level.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0427","tag_type":"warning","value":"No treatment interventions are evaluated; findings are descriptive and observational only.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0427","tag_type":"warning","value":"The MLCDP instrument records whether a life decision was affected but does not capture the direction of change (e.g., whether lifestyle modifications were beneficial or harmful), limiting interpretation of some findings such as increased physical activity.","value_numeric":null}],"summaries":{"what_studied":"This cross-sectional study evaluated how hidradenitis suppurativa (HS) affects major life-changing decisions (MLCD) in 123 adult HS patients at two Polish referral centres, using the validated 32-item Major Life-Changing Decision Profile (MLCDP) alongside measures of disease severity (Hurley staging, IHS4), quality of life (DLQI, HiSQOL), illness acceptance (AIS), and psychiatric symptoms (PHQ-9, GAD-7).","key_result":"87.8% of patients reported at least one affected MLCD (mean 6.2±5.2 decisions/patient; mean MLCDP total score 20.1±17.9 points). Most affected domains were social, physical, and intimate relationships — 64.2% avoided swimming, 56.1% avoided sexual relationships, and 75.6% changed eating habits. Hurley stage III patients had significantly higher MLCDP scores (37.1±25.1) vs. stage I (13.9±11.8, p=0.028) and stage II (16.4±11.6, p=0.031). MLCDP correlated most strongly with illness acceptance (r=−0.584, p<0.001) and disease-specific QoL (r=0.507, p<0.001).","limitations":"- Single-country, referral-centre design limits generalizability across healthcare systems and cultures.\n- Cross-sectional design prevents causal inference about the direction of relationships between HS severity and life decisions.\n- Self-report measures introduce recall bias, particularly for decisions made years earlier.","practice_takeaway":"Nearly 9 in 10 HS patients report the disease reshapes major life choices — from career to sexual relationships — especially those with Hurley stage III disease or low illness acceptance. Clinicians should routinely screen for psychosocial and life-course impact in HS and integrate psychological support alongside disease control."}},{"doi":"10.1093/bjd/ljag182","pmid":"42114107","title":"Cardiovascular Comorbidities and Risk in Hidradenitis Suppurativa: A Systematic Review and Meta-analysis","journal_title":"British Journal of Dermatology","journal_issn":"0007-0963","published_at":"2026-05-11T00:00:00.000Z","url":"https://doi.org/10.1093/bjd/ljag182","source_score":7,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-19T13:22:58.667Z","updated_at":"2026-05-19T13:22:58.667Z","tags":[{"paper_doi":"10.1093/bjd/ljag182","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag182","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag182","tag_type":"condition","value":"Cardiovascular Disease","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag182","tag_type":"condition","value":"Coronary Artery Disease","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag182","tag_type":"condition","value":"Heart Failure","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag182","tag_type":"condition","value":"Hidradenitis Suppurativa","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag182","tag_type":"condition","value":"Hypertension","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag182","tag_type":"condition","value":"Myocardial Infarction","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag182","tag_type":"condition","value":"Venous Thromboembolism","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag182","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag182","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag182","tag_type":"sample_size","value":"n=373689","value_numeric":373689},{"paper_doi":"10.1093/bjd/ljag182","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag182","tag_type":"study_design","value":"Systematic Review and Meta-Analysis","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag182","tag_type":"warning","value":"GRADE certainty of evidence was rated low for all outcomes due to observational study designs and inconsistent confounder adjustment — relative risk estimates should be interpreted cautiously.","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag182","tag_type":"warning","value":"Substantial statistical heterogeneity was present across most meta-analyses; pooled estimates may not be uniformly applicable across HS subpopulations.","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag182","tag_type":"warning","value":"The impact_flag 'practice_changing' reflects the clinical recommendation to add cardiovascular risk assessment to HS management, but the underlying evidence is observational and low certainty.","value_numeric":null}],"summaries":{"what_studied":"This systematic review and meta-analysis (25 studies, n=373,689 HS patients) quantified the prevalence of cardiovascular comorbidities in hidradenitis suppurativa (HS) and evaluated the association between HS and cardiovascular outcomes compared to individuals without HS, searching databases from inception through June 2025.","key_result":"Hypertension affected ~25% of HS patients. HS was associated with 1.3- to 1.8-fold increased relative risk for ischemic/coronary heart disease, composite cardiovascular disease, myocardial infarction, heart failure, venous thromboembolism, and all-cause mortality vs. non-HS comparators.","limitations":"- All included studies were observational, limiting causal inference.\n- Substantial heterogeneity was present across most meta-analyses.\n- Variability in confounder adjustment and non-standardized cardiovascular outcome definitions reduce certainty (GRADE: low).","practice_takeaway":"Clinicians managing HS should routinely assess cardiovascular risk, given a 1.3–1.8× elevated risk of major cardiovascular outcomes. Screening for hypertension, coronary artery disease, and heart failure is particularly warranted."}},{"doi":"10.1001/jamadermatol.2026.0916","pmid":"42090138","title":"Pediatric Skin Disease Frequencies and Dermatology Use by Race and Ethnicity in US Children’s Hospitals","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2026-05-06T00:00:00.000Z","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13150731/","source_score":10,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-05-11","doi":"10.1001/jamadermatol.2026.0916","days":"7","issn":"2168-6068","rank":"4","field":"Clinical Medicine","score":"10","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2026.0916","title":"Pediatric Skin Disease Frequencies and Dermatology Use by Race and Ethnicity in US Children's Hospitals.","journal":"JAMA dermatology","methods":"","results":"Of 536 776 patients, the mean (SD) age was 6.4 (6.3) years, 51.5% were female, and 0.2% were American Indian or Alaska Native, 6.4% Asian, 27.9% Black, 14.1% Hispanic, 0.3% Native Hawaiian or Other Pacific Islander, 8.4% non-Hispanic, 44.3% White, 4.3% multiple races, 5.5% unknown ethnicity, and 16.6% unknown race. Case counts were 377 970 for AD, 139 632 for acne, 54 305 for infantile hemangioma, 11 339 for psoriasis, and 5722 for HS. Electronic health record-derived frequencies varied across race and ethnicity groups. There were 10 469 (95% CI, 10 414-10 524) cases of AD per 100 000 Black children compared with 3099 (95% CI, 3083-3114) per 100 000 White children. There were 290 (95% CI, 280-300) cases of infantile hemangioma per 100 000 Black children compared with 764 (95% CI, 756-772) per 100 000 White children. Black children had a low proportion of dermatology use across all 5 conditions, yet high frequencies of AD, acne, and HS.","abstract":"$30","keywords":[],"pubmed_id":"42090138","conclusions":"","publication_date":"2026-05-06T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2026.0916","URL":"https://doi.org/10.1001/jamadermatol.2026.0916","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2848387/jamadermatology_quan_2026_oi_260013_1777558592.59238.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Pediatric Skin Disease Frequencies and Dermatology Use by Race and Ethnicity in US Children’s Hospitals"],"author":[{"given":"Nicolas G.","family":"Quan","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of Colorado, Aurora"}]},{"given":"Elizabeth","family":"Garcia-Creighton","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Colorado, Aurora"}]},{"given":"Molly","family":"Thapar","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Colorado, Aurora"}]},{"given":"Briana","family":"Kille","sequence":"additional","affiliation":[{"name":"Department of Research Informatics & Data Science, Children’s Hospital Colorado, Aurora"}]},{"given":"Josh","family":"Tucker","sequence":"additional","affiliation":[{"name":"Department of Research Informatics & Data Science, Children’s Hospital Colorado, Aurora"}]},{"given":"Sarah J.","family":"Schmiege","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado, Anschutz Medical Campus, Aurora"}]},{"given":"Markus D.","family":"Boos","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Pediatrics, University of Washington School of Medicine and Seattle Children’s Hospital, Seattle"}]},{"given":"Esteban","family":"Fernández Faith","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Pediatrics, Nationwide Children’s Hospital, The Ohio State University College of Medicine, Columbus"}]},{"given":"Amy S.","family":"Paller","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois"},{"name":"Department of Dermatology, Ann and Robert H. Lurie Children’s Hospital, Chicago, Illinois"}]},{"given":"Dawn H.","family":"Siegel","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Stanford University School of Medicine, Palo Alto, California"},{"name":"Department of Pediatrics, Stanford University School of Medicine, Palo Alto, California"}]},{"given":"Liza H.","family":"Siegel","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri"}]},{"given":"Roslyn T.","family":"Varki","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Pediatrics, Nemours Children’s Health System, Wilmington, Delaware"}]},{"given":"Albert C.","family":"Yan","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics and Dermatology, Children’s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania"}]},{"given":"Lucinda L.","family":"Kohn","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Colorado, Aurora"}]}],"issued":{"date-parts":[[2026,5,6]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":null,"created":{"date-time":"2026-05-06T15:31:43Z","timestamp":1778081503000,"date-parts":[[2026,5,6]]},"indexed":{"date-time":"2026-05-06T16:14:39Z","timestamp":1778084079008,"date-parts":[[2026,5,6]]},"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2848387"}},"subtitle":[],"deposited":{"date-time":"2026-05-06T15:31:44Z","timestamp":1778081504000,"date-parts":[[2026,5,6]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2026,5,6]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1016/j.acap.2025.102835","key":"doi260013r1","year":"2025","issue":"6","author":"Lee","volume":"25","first-page":null,"unstructured":null,"article-title":"Geographic maldistribution of pediatric dermatologists in relation to pediatric and family medicine residency programs.","journal-title":"Acad Pediatr","doi-asserted-by":"publisher"},{"DOI":"10.1111/pde.14748","key":"doi260013r2","year":"2021","issue":null,"author":"Toy","volume":"38","first-page":"13","unstructured":null,"article-title":"Barriers to healthcare access in pediatric dermatology: a systematic review.","journal-title":"Pediatr Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/pde.15914","key":"doi260013r3","year":"2025","issue":"3","author":"Gottlieb","volume":"42","first-page":"457","unstructured":null,"article-title":"An updated scoping review of disparities in pediatric atopic dermatitis.","journal-title":"Pediatr Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1093/bjd/ljae322","key":"doi260013r4","year":"2024","issue":"1","author":"Servattalab","volume":"192","first-page":"144","unstructured":null,"article-title":"Examining racial and ethnic disparities in diagnosis and access to care in infantile atopic dermatitis in the USA: a retrospective cohort study.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/pde.14755","key":"doi260013r5","year":"2021","issue":null,"author":"Kuo","volume":"38","first-page":"6","unstructured":null,"article-title":"A systematic scoping review of racial, ethnic, and socioeconomic health disparities in pediatric dermatology.","journal-title":"Pediatr Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2023.08.007","key":"doi260013r6","year":"2023","issue":"6","author":"Beiter","volume":"89","first-page":"1273","unstructured":null,"article-title":"Consideration of social context in understanding health disparities in pediatric dermatology.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2021.09.018","key":"doi260013r7","year":"2022","issue":"2","author":"Bajwa","volume":"86","first-page":"399","unstructured":null,"article-title":"Mixed evidence on the relationship between socioeconomic position and atopic dermatitis: a systematic review.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/pde.15455","key":"doi260013r8","year":"2023","issue":"6","author":"Reimer-Taschenbrecker","volume":"40","first-page":"1049","unstructured":null,"article-title":"Do socioeconomic factors impact atopic dermatitis outcome? A single-center study.","journal-title":"Pediatr Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaci.2023.11.013","key":"doi260013r9","year":"2024","issue":"4","author":"Croce","volume":"153","first-page":"1140","unstructured":null,"article-title":"Lower socioeconomic status may help explain racial disparities in asthma and atopic dermatitis prevalence: a mediation analysis.","journal-title":"J Allergy Clin Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2018.09.041","key":"doi260013r10","year":"2023","issue":"5","author":"Lie","volume":"88","first-page":"e221","unstructured":null,"article-title":"Lower socioeconomic status is associated with delayed access to care for infantile hemangioma: a cohort study.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamanetworkopen.2025.15094","key":"doi260013r11","year":"2025","issue":"6","author":"Sitarik","volume":"8","first-page":null,"unstructured":null,"article-title":"Phenotypes of atopic dermatitis and development of allergic diseases.","journal-title":"JAMA Netw Open","doi-asserted-by":"publisher"},{"DOI":"10.1111/pde.15387","key":"doi260013r12","year":"2023","issue":"5","author":"Noveir","volume":"40","first-page":"829","unstructured":null,"article-title":"Patterns and determinants of pediatric dermatologic care in the United States: an evaluation of the National Ambulatory Medical Care Survey from 2009 to 2015.","journal-title":"Pediatr Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jid.2018.04.001","key":"doi260013r13","year":"2018","issue":"10","author":"Garg","volume":"138","first-page":"2152","unstructured":null,"article-title":"Prevalence estimates for hidradenitis suppurativa among children and adolescents in the United States: a gender- and age-adjusted population analysis.","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi260013r14","year":"2023","issue":"459","author":"Zablotsky","volume":null,"first-page":"1","unstructured":null,"article-title":"Diagnosed allergic conditions in children aged 0-17 years: United States, 2021.","journal-title":"NCHS Data Brief","doi-asserted-by":null},{"DOI":"10.1111/pde.12075","key":"doi260013r15","year":"2013","issue":"4","author":"Amrock","volume":"30","first-page":"493","unstructured":null,"article-title":"Diverging racial trends in neonatal infantile hemangioma diagnoses, 1979-2006.","journal-title":"Pediatr Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/ijd.15805","key":"doi260013r16","year":"2022","issue":"6","author":"Monir","volume":"61","first-page":"727","unstructured":null,"article-title":"Association between atopic dermatitis and race from infancy to early childhood: a retrospective cohort study.","journal-title":"Int J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2020.5434","key":"doi260013r17","year":"2021","issue":"4","author":"Kirby","volume":"157","first-page":"379","unstructured":null,"article-title":"Recognizing the effects and disparities of pediatric hidradenitis suppurativa.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1136/amiajnl-2014-002743","key":"doi260013r18","year":"2014","issue":"4","author":"Forrest","volume":"21","first-page":"602","unstructured":null,"article-title":"PEDSnet: a National Pediatric Learning Health System.","journal-title":"J Am Med Inform Assoc","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2022.0351","key":"doi260013r19","year":"2022","issue":"5","author":"McKenzie","volume":"158","first-page":"547","unstructured":null,"article-title":"Evaluation of the prevalence and incidence of pediatric alopecia areata using electronic health record data.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1002/pds.5229","key":"doi260013r20","year":"2021","issue":"7","author":"Lee","volume":"30","first-page":"868","unstructured":null,"article-title":"Validation of claims-based algorithms to identify patients with psoriasis.","journal-title":"Pharmacoepidemiol Drug Saf","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2133.2010.10134.x","key":"doi260013r21","year":"2011","issue":"3","author":"Seminara","volume":"164","first-page":"602","unstructured":null,"article-title":"Validity of The Health Improvement Network (THIN) for the study of psoriasis.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2018.3114","key":"doi260013r22","year":"2018","issue":"11","author":"Tripathi","volume":"154","first-page":"1286","unstructured":null,"article-title":"Association of demographic and socioeconomic characteristics with differences in use of outpatient dermatology services in the United States.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.5070/D329160207","key":"doi260013r23","year":"2023","issue":"1","author":"Zagona-Prizio","volume":"29","first-page":null,"unstructured":null,"article-title":"Differences in accessing dermatology offices, primary care offices, and emergency departments between Hispanics and non-Hispanic White patients.","journal-title":"Dermatol Online J","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2017.08.035","key":"doi260013r24","year":"2017","issue":"6","author":"Fischer","volume":"77","first-page":"1060","unstructured":null,"article-title":"Racial and ethnic differences in health care utilization for childhood eczema: an analysis of the 2001-2013 Medical Expenditure Panel Surveys.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2024.01.067","key":"doi260013r25","year":"2024","issue":"6","author":"Harvey","volume":"91","first-page":"1189","unstructured":null,"article-title":"Integrating skin color assessments into clinical practice and research: a review of current approaches.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2014.06.032","key":"doi260013r26","year":"2014","issue":"4","author":"Feigenbaum","volume":"71","first-page":"656","unstructured":null,"article-title":"What should primary care providers know about pediatric skin conditions? A modified Delphi technique for curriculum development.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaip.2023.03.041","key":"doi260013r27","year":"2023","issue":"5","author":"Davis","volume":"11","first-page":"1376","unstructured":null,"article-title":"Managing atopic dermatitis in patients with skin of color.","journal-title":"J Allergy Clin Immunol Pract","doi-asserted-by":"publisher"},{"DOI":"10.1111/pde.12703","key":"doi260013r28","year":"2015","issue":"6","author":"Fogel","volume":"32","first-page":"e314","unstructured":null,"article-title":"A survey to assess perceived differences in referral pathways to board-certified pediatric dermatologists.","journal-title":"Pediatr Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.pedhc.2024.02.001","key":"doi260013r29","year":"2024","issue":"5","author":"Kozy","volume":"38","first-page":"651","unstructured":null,"article-title":"Referral patterns and diagnostic concordance in pediatric skin disorders.","journal-title":"J Pediatr Health Care","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.det.2023.02.003","key":"doi260013r30","year":"2023","issue":"3","author":"Adawi","volume":"41","first-page":"417","unstructured":null,"article-title":"Diagnosing atopic dermatitis in skin of color.","journal-title":"Dermatol Clin","doi-asserted-by":"publisher"},{"DOI":"10.1007/s11606-023-08392-0","key":"doi260013r31","year":"2023","issue":"14","author":"Anderson","volume":"38","first-page":"3247","unstructured":null,"article-title":"The bias of medicine in sickle cell disease.","journal-title":"J Gen Intern Med","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jpainsymman.2014.02.002","key":"doi260013r32","year":"2014","issue":"5","author":"Haywood","volume":"48","first-page":"934","unstructured":null,"article-title":"Perceived discrimination in health care is associated with a greater burden of pain in sickle cell disease.","journal-title":"J Pain Symptom Manage","doi-asserted-by":"publisher"},{"DOI":"10.1007/s11606-020-06336-6","key":"doi260013r33","year":"2022","issue":"2","author":"Schulson","volume":"37","first-page":"472","unstructured":null,"article-title":"National estimates of professional interpreter use in the ambulatory setting.","journal-title":"J Gen Intern Med","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi260013r34","year":"2016","issue":"1","author":"Brooks","volume":"99","first-page":"30","unstructured":null,"article-title":"Patient perspectives on the need for and barriers to professional medical interpretation.","journal-title":"R I Med J (2013)","doi-asserted-by":null},{"DOI":"10.1001/archpediatrics.2008.521","key":"doi260013r35","year":"2009","issue":"2","author":"Rajakumar","volume":"163","first-page":"108","unstructured":null,"article-title":"Racial differences in parents’ distrust of medicine and research.","journal-title":"Arch Pediatr Adolesc Med","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jid.2019.02.024","key":"doi260013r36","year":"2019","issue":"9","author":"Wan","volume":"139","first-page":"1906","unstructured":null,"article-title":"Racial/ethnic variation in use of ambulatory and emergency care for atopic dermatitis among US children.","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/pde.16021","key":"doi260013r37","year":"2025","issue":"5","author":"Thapar","volume":"42","first-page":"971","unstructured":null,"article-title":"What matters most to minoritized families in pediatric dermatology care: a qualitative study.","journal-title":"Pediatr Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamahealthforum.2022.1398","key":"doi260013r38","year":"2022","issue":"6","author":"Wallace","volume":"3","first-page":null,"unstructured":null,"article-title":"Disparities in health care spending and utilization among Black and White Medicaid enrollees.","journal-title":"JAMA Health Forum","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamanetworkopen.2024.31073","key":"doi260013r40","year":"2024","issue":"9","author":"Freed","volume":"7","first-page":null,"unstructured":null,"article-title":"Error rates in race and ethnicity designation across large pediatric health systems.","journal-title":"JAMA Netw Open","doi-asserted-by":"publisher"},{"DOI":"10.1111/pde.15891","key":"doi260013r41","year":"2025","issue":"4","author":"Onamusi","volume":"42","first-page":"806","unstructured":null,"article-title":"Racial differences in disease characteristics of pediatric hidradenitis suppurativa.","journal-title":"Pediatr Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jpeds.2023.113485","key":"doi260013r42","year":"2023","issue":null,"author":"Srinivasan","volume":"260","first-page":null,"unstructured":null,"article-title":"Disparities in pediatric specialty referral scheduling and completion.","journal-title":"J Pediatr","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2023.2008","key":"doi260013r43","year":"2023","issue":"8","author":"Long","volume":"159","first-page":"811","unstructured":null,"article-title":"Understanding discordant perceptions of disease severity between physicians and patients with eczema and psoriasis using structural equation modeling.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jpeds.2025.114604","key":"doi260013r44","year":"2025","issue":null,"author":"Yamamoto","volume":"283","first-page":null,"unstructured":null,"article-title":"Emergency versus outpatient care for pediatric atopic dermatitis: a population-based study of sociodemographic factors and health care utilization.","journal-title":"J Pediatr","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2021.2865","key":"doi260013r45","year":"2021","issue":"9","author":"Hallock","volume":"157","first-page":"1095","unstructured":null,"article-title":"Differences between children and adults with hidradenitis suppurativa.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s00403-024-03250-3","key":"doi260013r46","year":"2024","issue":"9","author":"Singal","volume":"316","first-page":"616","unstructured":null,"article-title":"Hidradenitis suppurativa in Black pediatric patients—a national analysis of the Kids’ Inpatient Database.","journal-title":"Arch Dermatol Res","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.pedn.2024.05.001","key":"doi260013r47","year":"2024","issue":null,"author":"Vestal","volume":"77","first-page":"e385","unstructured":null,"article-title":"Barriers and facilitators to accessing pediatric specialty care for rural-dwelling children with complex chronic conditions: an integrative review.","journal-title":"J Pediatr Nurs","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jpeds.2012.07.022","key":"doi260013r48","year":"2013","issue":"2","author":"Zuckerman","volume":"162","first-page":"409","unstructured":null,"article-title":"Barriers to specialty care and specialty referral completion in the community health center setting.","journal-title":"J Pediatr","doi-asserted-by":"publisher"},{"DOI":"10.1186/s12887-023-04400-8","key":"doi260013r49","year":"2023","issue":"1","author":"Bohnhoff","volume":"23","first-page":"576","unstructured":null,"article-title":"General and subspecialist pediatrician perspectives on barriers and strategies for referral: a latent profile analysis.","journal-title":"BMC Pediatr","doi-asserted-by":"publisher"},{"DOI":"10.1377/hlthaff.2021.01409","key":"doi260013r50","year":"2022","issue":"2","author":"Eberth","volume":"41","first-page":"237","unstructured":null,"article-title":"The problem of the color line: spatial access to hospital services for minoritized racial and ethnic groups.","journal-title":"Health Aff (Millwood)","doi-asserted-by":"publisher"},{"DOI":"10.2196/67728","key":"doi260013r51","year":"2025","issue":null,"author":"McDowell","volume":"8","first-page":null,"unstructured":null,"article-title":"Provider perspectives on pediatric store-and-forward teledermatology at Boston Medical Center: cross-sectional survey.","journal-title":"JMIR Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/pde.14762","key":"doi260013r52","year":"2021","issue":null,"author":"Rehmus","volume":"38","first-page":"174","unstructured":null,"article-title":"Integrating dermatology services into a social pediatrics network: 8 years of experience in the RICHER (Responsive, Interdisciplinary/Intersectoral, Child/Community, Health, Education and Research) program.","journal-title":"Pediatr Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/pde.15698","key":"doi260013r53","year":"2024","issue":"6","author":"Crockett","volume":"41","first-page":"1114","unstructured":null,"article-title":"Pediatric dermatology eConsultation: insights to reduce barriers to utilization and increase access to care.","journal-title":"Pediatr Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jdrv.2024.12.004","key":"doi260013r54","year":"2025","issue":null,"author":"Proffer","volume":"3","first-page":"60","unstructured":null,"article-title":"Disparities in specialty care: a review of US nonprofit initiatives.","journal-title":"JAAD Reviews","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2020.09.019","key":"doi260013r55","year":"2021","issue":"3","author":"Franciosi","volume":"84","first-page":"769","unstructured":null,"article-title":"Understanding the impact of teledermatology on no-show rates and health care accessibility: a retrospective chart review.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi260013r39","year":"2024","issue":null,"author":"Garcia-Creighton","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"reference-count":55,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,5,6]]},"references-count":55,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1001/jamadermatol.2026.0916","is_oa":true,"title":"Pediatric Skin Disease Frequencies and Dermatology Use by Race and Ethnicity in US Children’s Hospitals","updated":"2026-05-12T08:54:10+00:00","published_date":"2026-05-06","best_oa_location":{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13150731/","pmh_id":"oai:pubmedcentral.nih.gov:13150731","url_for_pdf":null,"url_for_landing_page":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13150731/"}}},"created_at":"2026-05-12T13:18:03.403Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1001/jamadermatol.2026.0916","tag_type":"age_group","value":"pediatric","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0916","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0916","tag_type":"condition","value":"Acne","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0916","tag_type":"condition","value":"Atopic Dermatitis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0916","tag_type":"condition","value":"Hidradenitis Suppurativa","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0916","tag_type":"condition","value":"Infantile Hemangioma","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0916","tag_type":"condition","value":"Psoriasis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0916","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0916","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0916","tag_type":"sample_size","value":"n=536776","value_numeric":536776},{"paper_doi":"10.1001/jamadermatol.2026.0916","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0916","tag_type":"study_design","value":"Cross-Sectional Study","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0916","tag_type":"warning","value":"Full text is under embargo until May 2027; summary is based solely on the abstract and results excerpt — detailed methodology, adjusted analyses, and per-condition dermatology use rates by race/ethnicity are not available for review.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0916","tag_type":"warning","value":"impact_flag set to 'safety_signal' to highlight the potential care gap for Black children, though the authors note further research is needed to confirm whether this represents a true gap versus appropriate care routing.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0916","tag_type":"warning","value":"The 'non-Hispanic' category (8.4%) appears to be listed separately from White (44.3%), suggesting possible ambiguity or overlap in how race and ethnicity were coded in the EHR data.","value_numeric":null}],"summaries":{"what_studied":"This multicenter cross-sectional study examined the frequency of 5 pediatric skin conditions (atopic dermatitis, acne, infantile hemangioma, psoriasis, and hidradenitis suppurativa) and rates of dermatology specialty care use, stratified by race and ethnicity, across 8 US children's hospitals in the PEDSnet system from January 2009 to July 2022.","key_result":"Among 536,776 children, Black children had the highest EHR-derived frequency of atopic dermatitis (10,469 per 100,000 vs. 3,099 per 100,000 White children) and the lowest frequency of infantile hemangioma (290 vs. 764 per 100,000 White children), yet had a low proportion of dermatology specialty care use across all 5 conditions despite high frequencies of AD, acne, and HS.","limitations":"- EHR-derived diagnoses may reflect coding practices and access to care rather than true disease prevalence.\n- Study limited to children's hospital networks (PEDSnet), which may not represent community or primary care settings.\n- It is unclear whether lower dermatology use in Black children reflects appropriate care routing or actual gaps in specialty access.","practice_takeaway":"Black children carry a disproportionately high burden of atopic dermatitis, acne, and hidradenitis suppurativa but are less likely to reach pediatric dermatology care — clinicians should actively consider referral pathways and potential access barriers for these patients."}},{"doi":"10.1001/jamadermatol.2026.0895","pmid":"42090176","title":"Environmental and Social Drivers of Hidradenitis Suppurativa","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2026-05-06T00:00:00.000Z","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13150727/","source_score":11,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-05-11","doi":"10.1001/jamadermatol.2026.0895","days":"7","issn":"2168-6068","rank":"3","field":"Clinical Medicine","score":"11","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2026.0895","title":"Environmental and Social Drivers of Hidradenitis Suppurativa.","journal":"JAMA dermatology","methods":"","results":"","abstract":"This cross-sectional study of US adults with hidradenitis suppurativa in the Boston metropolitan area uses spatial epidemiological methods to analyze disease distribution by socioenvironmental characteristics.","keywords":[],"pubmed_id":"42090176","conclusions":"","publication_date":"2026-05-06T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2026.0895","URL":"https://doi.org/10.1001/jamadermatol.2026.0895","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2848390/jamadermatology_baker_2026_ld_260006_1777558597.4677.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Environmental and Social Drivers of Hidradenitis Suppurativa"],"author":[{"given":"Natalie M.","family":"Baker","sequence":"first","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts"}]},{"given":"Karla","family":"Santiago-Soltero","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts"},{"name":"Ponce Health Sciences University, Ponce, Puerto Rico"}]},{"given":"Viviana","family":"Flores","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Boston Medical Center, Boston, Massachusetts"}]},{"given":"Subin","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tufts Medical Center, Boston, Massachusetts"}]},{"given":"Bruna Galvao","family":"de Oliveira Wafae","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts"}]},{"given":"Stephanie R.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts"},{"name":"Department of Dermatology, Tufts Medical Center, Boston, Massachusetts"}]},{"given":"Gabriela","family":"Cobos","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tufts Medical Center, Boston, Massachusetts"}]},{"given":"Priya","family":"Manjaly","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Boston Medical Center, Boston, Massachusetts"}]},{"given":"Martina L.","family":"Porter","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts"}]},{"given":"Gregory","family":"Orlowski","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Boston Medical Center, Boston, Massachusetts"}]},{"given":"Kanglin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Government, Harvard University, Cambridge, Massachusetts"}]},{"given":"Leandra A.","family":"Barnes","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Stanford University, Palo Alto, California"}]},{"given":"Aileen Y.","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco"}]},{"given":"Alexandra P.","family":"Charrow","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts"}]}],"issued":{"date-parts":[[2026,5,6]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":null,"created":{"date-time":"2026-05-06T15:31:05Z","timestamp":1778081465000,"date-parts":[[2026,5,6]]},"indexed":{"date-time":"2026-05-06T16:16:12Z","timestamp":1778084172716,"date-parts":[[2026,5,6]]},"subject":[],"abstract":"This cross-sectional study of US adults with hidradenitis suppurativa in the Boston metropolitan area uses spatial epidemiological methods to analyze disease distribution by socioenvironmental characteristics.","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2848390"}},"subtitle":[],"deposited":{"date-time":"2026-05-06T15:31:12Z","timestamp":1778081472000,"date-parts":[[2026,5,6]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2026,5,6]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1001/jamadermatol.2025.1190","key":"dld260006r1","year":"2025","issue":"7","author":"Chang","volume":"161","first-page":"707","unstructured":null,"article-title":"Neighborhood socioeconomic status and new hidradenitis suppurativa diagnoses in a single health system.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s00403-023-02759-3","key":"dld260006r2","year":"2023","issue":"1","author":"Singh","volume":"316","first-page":"49","unstructured":null,"article-title":"Increased ambient outdoor temperatures are associated with increased disease flaring in hidradenitis suppurativa.","journal-title":"Arch Dermatol Res","doi-asserted-by":"publisher"},{"DOI":"10.3390/ijerph20032526","key":"dld260006r3","year":"2023","issue":"3","author":"Fadadu","volume":"20","first-page":"3","unstructured":null,"article-title":"Air pollution and atopic dermatitis, from molecular mechanisms to population-level evidence: a review.","journal-title":"Int J Environ Res Public Health","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(25)01919-1","key":"dld260006r4","year":"2025","issue":"10521","author":"Romanello","volume":"406","first-page":"2804","unstructured":null,"article-title":"The 2025 report of the Lancet Countdown on health and climate change: climate change action offers a lifeline.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1111/obr.13171","key":"dld260006r5","year":"2021","issue":"4","author":"Dixon","volume":"22","first-page":null,"unstructured":null,"article-title":"Associations between the built environment and dietary intake, physical activity, and obesity: a scoping review of reviews.","journal-title":"Obes Rev","doi-asserted-by":"publisher"},{"DOI":null,"key":"dld260006r6","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Massachusetts Department of Public Health. How segregation creates communities of color in MA. Mass.gov. Accessed August 25, 2025. https://www.mass.gov/info-details/how-segregation-creates-communities-of-color-in-ma","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"reference-count":6,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,5,6]]},"references-count":6,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1001/jamadermatol.2026.0895","is_oa":true,"title":"Environmental and Social Drivers of Hidradenitis Suppurativa","updated":"2026-05-12T08:54:10+00:00","published_date":"2026-05-06","best_oa_location":{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13150727/","pmh_id":"oai:pubmedcentral.nih.gov:13150727","url_for_pdf":null,"url_for_landing_page":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13150727/"}}},"created_at":"2026-05-12T13:18:03.150Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1001/jamadermatol.2026.0895","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0895","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0895","tag_type":"condition","value":"Hidradenitis Suppurativa","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0895","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0895","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0895","tag_type":"study_design","value":"Cross-Sectional Study","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0895","tag_type":"warning","value":"Full text is embargoed until May 6, 2027; only the abstract is publicly available. Key results, sample size, statistical findings, and detailed methods could not be extracted.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0895","tag_type":"warning","value":"Sex of study population is not reported in the abstract.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0895","tag_type":"warning","value":"Study is geographically limited to the Boston metropolitan area, which may limit generalizability to other US regions.","value_numeric":null}],"summaries":{"what_studied":"A cross-sectional study of US adults with hidradenitis suppurativa (HS) in the Boston metropolitan area, using spatial epidemiological methods to examine how socioenvironmental characteristics relate to disease distribution.","limitations":"Full text is under embargo until May 2027; only the abstract is available, so specific results, sample size, and detailed methods cannot be assessed."}},{"doi":"10.1001/jamadermatol.2026.0155","pmid":"41848710","title":"Lutikizumab in Adults With Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2026-03-18T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2026.0155","source_score":25,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-24T13:22:59.517Z","updated_at":"2026-05-24T13:22:59.517Z","tags":[{"paper_doi":"10.1001/jamadermatol.2026.0155","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0155","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0155","tag_type":"condition","value":"Hidradenitis Suppurativa","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0155","tag_type":"generic","value":"lutikizumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0155","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0155","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0155","tag_type":"modality","value":"IL-1 Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0155","tag_type":"sample_size","value":"n=153","value_numeric":153},{"paper_doi":"10.1001/jamadermatol.2026.0155","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0155","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0155","tag_type":"warning","value":"Bayesian analysis with posterior probabilities was used rather than traditional frequentist p-values; clinical interpretation of the 89.3% vs 98.5% thresholds may vary by reader.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0155","tag_type":"warning","value":"Publication date (2026-03-18) is slightly in the future relative to today's date; content is taken as provided and may represent advance online publication.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0155","tag_type":"warning","value":"The 'practice_changing' flag reflects a promising phase 2 signal in a hard-to-treat population, but phase 3 confirmation is needed before routine clinical adoption.","value_numeric":null}],"summaries":{"what_studied":"Phase 2 double-blind RCT evaluating lutikizumab (dual IL-1α/1β antagonist) at three dose regimens vs. placebo over 16 weeks in 153 adults with moderate-to-severe HS who had failed prior anti-TNF therapy across 45 sites in 8 countries.","key_result":"HiSCR50 at week 16 was achieved by 59.5% (300 mg every other week) and 48.7% (300 mg every week) vs. 35.0% placebo, with posterior probabilities of positive treatment effect of 98.5% and 89.3%, respectively; the 100 mg every other week arm did not separate from placebo (27.0%, 22.8%). Pain response (NRS30) was roughly 35% in both 300 mg arms vs. 12.9% placebo. No deaths, neutropenia, serious hypersensitivity, MACE, or opportunistic infections occurred.","limitations":"Short 16-week treatment period limits conclusions about durability; phase 2 sample sizes per arm are small (n≈37–40 per arm), reducing power for subgroup analyses; Bayesian design means results are probabilistic rather than traditional hypothesis-tested.","practice_takeaway":"For HS patients who have failed anti-TNF therapy, lutikizumab 300 mg (weekly or every other week) showed meaningful clinical responses with a clean short-term safety profile — supporting IL-1α/1β dual blockade as a promising next step pending phase 3 confirmation."}},{"doi":"10.1001/jamadermatol.2025.5112","pmid":"41432947","title":"Health System Experiences and Care Engagement in Latine Patients With Hidradenitis Suppurativa","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2025-12-23T00:00:00.000Z","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12728727/","source_score":21,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-12-25","doi":"10.1001/jamadermatol.2025.5112","days":"30","issn":"2168-6068","rank":"5","field":"Clinical Medicine","score":"21","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2025.5112","title":"Health System Experiences and Care Engagement in Latine Patients With Hidradenitis Suppurativa.","journal":"JAMA dermatology","methods":"","results":"Among the 24 Latine patients included in the analysis, the median (IQR) age was 37.5 (32.75-44.25) years, 17 (71%) were female, 11 (46%) preferred Spanish, and 19 (79%) had Hurley stage 2 or 3 disease. Three themes were developed. First, unaddressed wound care and pain management burdens patients with self-directed care, with 2 subthemes: (1) insufficient guidance for patients' wound care and pain management and (2) self-directed care in response to limited health care system support for pain management and wound care creates personal burden. Second, perceived discrimination during dermatology visits leads to avoidance of care. Third, patient-centered care remains a challenge with phone or video interpreter-mediated communication.","abstract":"$32","keywords":[],"pubmed_id":"41432947","conclusions":"","publication_date":"2025-12-23T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2025.5112","URL":"https://doi.org/10.1001/jamadermatol.2025.5112","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2842852/jamadermatology_hernandez_2025_oi_250062_1765296583.09685.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Health System Experiences and Care Engagement in Latine Patients With Hidradenitis Suppurativa"],"author":[{"given":"Yanel","family":"Hernandez","sequence":"first","affiliation":[{"name":"University of California, San Francisco School of Medicine, San Francisco"}]},{"given":"Nathaly","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, School of Medicine, Milwaukee"}]},{"given":"Raveena","family":"Ghanshani","sequence":"additional","affiliation":[{"name":"Keck School of Medicine, University of Southern California, Los Angeles"}]},{"given":"Herbert B.","family":"Castillo Valladares","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco, School of Medicine, San Francisco"},{"name":"Department of Dermatology, Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, California"}]},{"given":"Erin H.","family":"Amerson","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco, School of Medicine, San Francisco"},{"name":"Department of Dermatology, Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, California"}]},{"given":"Haley B.","family":"Naik","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco, School of Medicine, San Francisco"}]},{"given":"Jennifer L.","family":"Hsiao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Southern California, Los Angeles"}]},{"given":"Jennifer","family":"James","sequence":"additional","affiliation":[{"name":"Department of Social and Behavioral Sciences, University of California, San Francisco School of Nursing, San Francisco"}]},{"given":"Sara L.","family":"Ackerman","sequence":"additional","affiliation":[{"name":"Department of Social and Behavioral Sciences, University of California, San Francisco School of Nursing, San Francisco"}]},{"given":"Aileen Y.","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco, School of Medicine, San Francisco"},{"name":"Department of Dermatology, Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, California"},{"name":"Viewpoints Editor, JAMA Dermatology"}]}],"issued":{"date-parts":[[2025,12,23]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":null,"created":{"date-time":"2025-12-23T16:00:50Z","timestamp":1766505650000,"date-parts":[[2025,12,23]]},"indexed":{"date-time":"2025-12-23T16:57:26Z","timestamp":1766509046878,"date-parts":[[2025,12,23]]},"subject":[],"abstract":"$33","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2842852"}},"subtitle":[],"deposited":{"date-time":"2025-12-23T16:00:51Z","timestamp":1766505651000,"date-parts":[[2025,12,23]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2025,12,23]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1016/j.jnma.2022.08.002","key":"doi250062r1","year":"2022","issue":"6","author":"Serrano","volume":"114","first-page":"613","unstructured":null,"article-title":"Racial disparities of delay in diagnosis and dermatologic care for hidradenitis suppurativa.","journal-title":"J Natl Med Assoc","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jdin.2021.01.007","key":"doi250062r2","year":"2021","issue":null,"author":"Kilgour","volume":"3","first-page":"42","unstructured":null,"article-title":"Hidradenitis suppurativa in patients of color is associated with increased disease severity and healthcare utilization: A retrospective analysis of 2 U.S. cohorts.","journal-title":"JAAD Int","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.18818","key":"doi250062r3","year":"2020","issue":"6","author":"Shukla","volume":"182","first-page":"1490","unstructured":null,"article-title":"Identifying barriers to care and research in hidradenitis suppurativa: findings from a patient engagement event.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2023.0486","key":"doi250062r4","year":"2023","issue":"5","author":"Barnes","volume":"159","first-page":"510","unstructured":null,"article-title":"Patient perspectives of health system barriers to accessing care for hidradenitis suppurativa: a qualitative study.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.20523","key":"doi250062r5","year":"2021","issue":"5","author":"Howells","volume":"185","first-page":"921","unstructured":null,"article-title":"Thematic synthesis of the experiences of people with hidradenitis suppurativa: a systematic review.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2019.06.1301","key":"doi250062r6","year":"2020","issue":"2","author":"Garg","volume":"82","first-page":"366","unstructured":null,"article-title":"Evaluating patients’ unmet needs in hidradenitis suppurativa: results from the Global Survey Of Impact and Healthcare Needs (VOICE) project.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s11606-022-07995-3","key":"doi250062r7","year":"2023","issue":"5","author":"Escobedo","volume":"38","first-page":"1264","unstructured":null,"article-title":"Barriers in healthcare for Latinx patients with limited English proficiency-a narrative review.","journal-title":"J Gen Intern Med","doi-asserted-by":"publisher"},{"DOI":"10.1186/s12913-018-3138-2","key":"doi250062r8","year":"2018","issue":"1","author":"Luque","volume":"18","first-page":"310","unstructured":null,"article-title":"Access to health care for uninsured Latina immigrants in South Carolina.","journal-title":"BMC Health Serv Res","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2024.5391","key":"doi250062r9","year":"2025","issue":"3","author":"Gonzalez","volume":"161","first-page":"291","unstructured":null,"article-title":"Latine patients’ beliefs, attitudes, and experience with psoriasis.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1186/s12889-024-20000-2","key":"doi250062r10","year":"2024","issue":"1","author":"Niu","volume":"24","first-page":"2690","unstructured":null,"article-title":"Barriers and facilitators to skin cancer prevention among Hispanics: a qualitative study.","journal-title":"BMC Public Health","doi-asserted-by":"publisher"},{"DOI":"10.1097/JW9.0000000000000096","key":"doi250062r11","year":"2023","issue":"3","author":"Poondru","volume":"9","first-page":null,"unstructured":null,"article-title":"Wound care counseling of patients with hidradenitis suppurativa: perspectives of dermatologists.","journal-title":"Int J Womens Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2023.07.1037","key":"doi250062r12","year":"2023","issue":"6","author":"Chopra","volume":"89","first-page":"1289","unstructured":null,"article-title":"Wound care for patients with hidradenitis suppurativa: recommendations of an international panel of experts.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1300/J096v11n02_06","key":"doi250062r13","year":"2006","issue":"2","author":"Arcury","volume":"11","first-page":"27","unstructured":null,"article-title":"Treating skin disease: self-management behaviors of Latino farmworkers.","journal-title":"J Agromedicine","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2025.0404","key":"doi250062r14","year":"2025","issue":"7","author":"Castillo Valladares","volume":"161","first-page":"739","unstructured":null,"article-title":"Dermatologic care and skin health of migrant populations in the US: a scoping review.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1093/bjd/ljad215","key":"doi250062r15","year":"2023","issue":"5","author":"Sow","volume":"189","first-page":"624","unstructured":null,"article-title":"Healthcare experiences among patients with hidradenitis suppurativa: a qualitative study.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1093/bjd/ljac018","key":"doi250062r16","year":"2023","issue":"1","author":"Orenstein","volume":"188","first-page":"41","unstructured":null,"article-title":"Pain experiences among those living with hidradenitis suppurativa: a qualitative study.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.socscimed.2022.115096","key":"doi250062r17","year":"2022","issue":null,"author":"Sobo","volume":"305","first-page":null,"unstructured":null,"article-title":"Addressing COVID-19 vaccination equity for Hispanic/Latino communities by attending to aguantarismo: A Californian US-Mexico border perspective.","journal-title":"Soc Sci Med","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jpain.2024.104550","key":"doi250062r18","year":"2024","issue":"9","author":"Ruben","volume":"25","first-page":null,"unstructured":null,"article-title":"Documenting race and gender biases in pain assessment and a novel intervention designed to reduce biases.","journal-title":"J Pain","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2025.3620","key":"doi250062r19","year":"2025","issue":null,"author":"Miller","volume":null,"first-page":null,"unstructured":null,"article-title":"Facilitators and barriers to the timely diagnosis and treatment of melanoma in Latino persons.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/ijd.14870","key":"doi250062r20","year":"2020","issue":"6","author":"Collier","volume":"59","first-page":"744","unstructured":null,"article-title":"Comprehensive approach to managing hidradenitis suppurativa patients.","journal-title":"Int J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1146/annurev-publhealth-052620-103528","key":"doi250062r23","year":"2022","issue":null,"author":"Vela","volume":"43","first-page":"477","unstructured":null,"article-title":"Eliminating explicit and implicit biases in health care: evidence and research Needs.","journal-title":"Annu Rev Public Health","doi-asserted-by":"publisher"},{"DOI":"10.1136/bmjoq-2024-003227","key":"doi250062r24","year":"2025","issue":"2","author":"Ruiz","volume":"14","first-page":null,"unstructured":null,"article-title":"Comparing remote and in-person interpretation experiences for clinicians and Spanish-speaking patients with limited English proficiency: a mixed methods study.","journal-title":"BMJ Open Qual","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi250062r21","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Brach? C, ed. AHRQ Health Literacy Universal Precautions Toolkit, 3rd Edition. Rockville, MD. Agency for Healthcare Research and Quality. AHRQ Publication No. 23-0075. Accessed on October 20, 2025. https://www.ahrq.gov/sites/default/files/publications2/files/health-literacy-universal-precautions-toolkit-3rd-edition.pdf","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi250062r22","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"United States Census Bureau. California: 2020 census. Accessed October 17, 2025. https://www.census.gov/library/stories/state-by-state/california.html#race-ethnicity","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"reference-count":24,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,12,23]]},"references-count":24,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1001/jamadermatol.2025.5112","is_oa":true,"title":"Health System Experiences and Care Engagement in Latine Patients With Hidradenitis Suppurativa","updated":"2025-12-27T00:44:22+00:00","published_date":"2025-12-23","best_oa_location":{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12728727/","pmh_id":"oai:pubmedcentral.nih.gov:12728727","url_for_pdf":null,"url_for_landing_page":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12728727/"}}},"created_at":"2026-01-19T09:31:36.873Z","updated_at":"2026-01-21T12:05:26.220Z","tags":[{"paper_doi":"10.1001/jamadermatol.2025.5112","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5112","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5112","tag_type":"condition","value":"Hidradenitis Suppurativa","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5112","tag_type":"sample_size","value":"n=24","value_numeric":24},{"paper_doi":"10.1001/jamadermatol.2025.5112","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5112","tag_type":"study_design","value":"Qualitative Study","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5112","tag_type":"warning","value":"Design classified as a qualitative study based on semistructured interviews and thematic analysis.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5112","tag_type":"warning","value":"Findings are descriptive themes without prevalence estimates or effect sizes.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5112","tag_type":"warning","value":"Recruitment from four California sites may limit generalizability.","value_numeric":null}],"summaries":{"limitations":"Single-state, four-site sample (n=24) may limit generalizability; qualitative design provides themes without quantifying how common each experience was.","what_studied":"Semistructured interviews with 24 English- or Spanish-preferring Latine adults with hidradenitis suppurativa from 2 academic medical centers and 2 county hospitals in California (June 2024–March 2025) explored how health system factors shaped their care experiences and implementation of care plans.","key_result":"Three themes emerged: (1) unaddressed wound care and pain led to self-directed care and personal burden; (2) perceived discrimination during dermatology visits prompted avoidance of care; (3) phone or video interpreter–mediated communication challenged patient-centered care.","practice_takeaway":"Prioritize wound care and pain management within multidisciplinary plans for Latine patients with HS, use patient-centered interpreter strategies, and address perceived discrimination to reduce avoidance of care."}},{"doi":"10.1001/jamadermatol.2025.5010","pmid":"41405899","title":"Hidradenitis Suppurativa and Smoking, Obesity, Psoriasis, Inflammatory Bowel Disease, and Systemic Sclerosis","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2025-12-17T00:00:00.000Z","url":"https://pure.au.dk/portal/en/publications/aa2f0639-3762-48dd-aff4-c2847d9568b9","source_score":32,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-12-19","doi":"10.1001/jamadermatol.2025.5010","days":"30","issn":"2168-6068","rank":"10","field":"Clinical Medicine","score":"32","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2025.5010","title":"Hidradenitis Suppurativa and Smoking, Obesity, Psoriasis, Inflammatory Bowel Disease, and Systemic Sclerosis: Results From A 2-Sample Mendelian Randomization Study.","journal":"JAMA dermatology","methods":"","results":"$34","abstract":"$35","keywords":[],"pubmed_id":"41405899","conclusions":"","publication_date":"2025-12-17T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2025.5010","URL":"https://doi.org/10.1001/jamadermatol.2025.5010","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2842470/jamadermatology_kjrsgaard_andersen_2025_oi_250061_1764627614.99488.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Hidradenitis Suppurativa and Smoking, Obesity, Psoriasis, Inflammatory Bowel Disease, and Systemic Sclerosis"],"author":[{"given":"Rune","family":"Kjærsgaard Andersen","sequence":"first","affiliation":[{"name":"Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen University Hospitals, Gentofte, Denmark"},{"name":"Department of Immunology and Microbiology, Leo Foundation Skin Immunology Research Center, University of Copenhagen, Denmark"}]},{"given":"Peter Theut","family":"Riis","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Zealand University Hospital, Roskilde, Denmark"}]},{"given":"Claus","family":"Zachariae","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen University Hospitals, Gentofte, Denmark"},{"name":"Deptartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark"}]},{"given":"Simon Francis","family":"Thomsen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark"}]},{"given":"Liam","family":"Quin","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Zealand University Hospital, Køge, Denmark"}]},{"given":"Khoa Manh","family":"Dinh","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark"},{"name":"Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark"}]},{"given":"Karina","family":"Banasik","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Copenhagen University Hospitals, Hvidovre, Hvidovre, Denmark"},{"name":"Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}]},{"given":"Søren","family":"Brunak","sequence":"additional","affiliation":[{"name":"Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, University of Copenhagen, Copenhagen, Denmark"}]},{"given":"Thomas","family":"Hansen","sequence":"additional","affiliation":[{"name":"Translational Research Centre, Copenhagen University Hospital, Rigshospitalet-Glostrup, Copenhagen, Denmark"}]},{"given":"Henrik","family":"Hjalgrim","sequence":"additional","affiliation":[{"name":"Deptartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark"},{"name":"Danish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark"},{"name":"Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark"}]},{"given":"Erik","family":"Sørensen","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark"}]},{"given":"Christina","family":"Mikkelsen","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark"},{"name":"Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Science, Copenhagen University, Copenhagen, Denmark"}]},{"given":"Henrik","family":"Ullum","sequence":"additional","affiliation":[{"name":"Statens Serum Institut, Copenhagen, Denmark"}]},{"given":"Mette","family":"Nyegaard","sequence":"additional","affiliation":[{"name":"Department of Health Science and Technology, Aalborg University, Gistrup, Denmark"}]},{"given":"Mie Topholm","family":"Bruun","sequence":"additional","affiliation":[{"name":"Clinical Immunology Research Unit, Department of Clinical Immunology, Odense University Hospital, Odense, Denmark"}]},{"given":"Christian","family":"Erikstrup","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark"},{"name":"Department of Clinical Medicine, Aarhus University, Aarhus, Denmark"}]},{"given":"Sisse Rye","family":"Ostrowski","sequence":"additional","affiliation":[{"name":"Deptartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark"},{"name":"Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark"}]},{"given":"Liv","family":"Eidsmo","sequence":"additional","affiliation":[{"name":"Department of Immunology and Microbiology, Leo Foundation Skin Immunology Research Center, University of Copenhagen, Denmark"},{"name":"Division of Dermatovenereology, Department of Medicine Solna, Karolinska Institutet, Sweden and ME Gastro/HUD/Reuma, Karolinska University Hospital Sweden"}]},{"given":"Ditte Marie","family":"Lindhardt Saunte","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen University Hospitals, Gentofte, Denmark"},{"name":"Deptartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark"}]},{"given":"Ole Birger Vesterager","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Deptartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark"},{"name":"Department of Clinical Immunology, Zealand University Hospital, Køge, Denmark"}]},{"given":"Gregor Borut Ernst","family":"Jemec","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen University Hospitals, Gentofte, Denmark"},{"name":"Deptartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark"}]}],"issued":{"date-parts":[[2025,12,17]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":null,"created":{"date-time":"2025-12-17T16:00:32Z","timestamp":1765987232000,"date-parts":[[2025,12,17]]},"indexed":{"date-time":"2025-12-17T16:02:48Z","timestamp":1765987368667,"date-parts":[[2025,12,17]]},"subject":[],"abstract":"$36","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2842470"}},"subtitle":["Results From A 2-Sample Mendelian Randomization Study"],"deposited":{"date-time":"2025-12-17T16:00:34Z","timestamp":1765987234000,"date-parts":[[2025,12,17]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2025,12,17]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1046/j.1468-3083.2000.00087.x","key":"doi250061r1","year":"2000","issue":"5","author":"von der Werth","volume":"14","first-page":"389","unstructured":null,"article-title":"The natural history of hidradenitis suppurativa.","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMcp1014163","key":"doi250061r2","year":"2012","issue":"2","author":"Jemec","volume":"366","first-page":"158","unstructured":null,"article-title":"Clinical practice. hidradenitis suppurativa.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1111/ijd.14651","key":"doi250061r3","year":"2020","issue":"2","author":"Kjaersgaard Andersen","volume":"59","first-page":"216","unstructured":null,"article-title":"Psoriasis as a comorbidity of hidradenitis suppurativa.","journal-title":"Int J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2019.0891","key":"doi250061r4","year":"2019","issue":"9","author":"Chen","volume":"155","first-page":"1022","unstructured":null,"article-title":"Association of hidradenitis suppurativa with inflammatory bowel disease: a systematic review and meta-analysis.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jdin.2024.07.017","key":"doi250061r5","year":"2024","issue":null,"author":"Kassels","volume":"17","first-page":"55","unstructured":null,"article-title":"Hidradenitis suppurativa is associated with inflammatory arthritis, systemic lupus erythematosus, and other autoimmune diseases: a retrospective population-level study.","journal-title":"JAAD Int","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2024.11.050","key":"doi250061r6","year":"2025","issue":"4","author":"Andersen","volume":"92","first-page":"761","unstructured":null,"article-title":"A genome-wide association meta-analysis links hidradenitis suppurativa to common and rare sequence variants causing disruption of the Notch and Wnt/ß-catenin signaling pathways.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(24)02475-9","key":"doi250061r7","year":"2025","issue":"10476","author":"Sabat","volume":"405","first-page":"420","unstructured":null,"article-title":"Hidradenitis suppurativa.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2015.07.045","key":"doi250061r8","year":"2015","issue":"5","author":"Prens","volume":"73","first-page":"S8","unstructured":null,"article-title":"Pathophysiology of hidradenitis suppurativa: an update.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s10875-023-01518-3","key":"doi250061r9","year":"2023","issue":"6","author":"Colvin","volume":"43","first-page":"1040","unstructured":null,"article-title":"Inborn errors of immunity in hidradenitis suppurativa pathogenesis and disease burden.","journal-title":"J Clin Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.19210","key":"doi250061r10","year":"2020","issue":"5","author":"Ingram","volume":"183","first-page":"950","unstructured":null,"article-title":"Prevalence of hidradenitis suppurativa is one percent of the population of Wales using the Secure Anonymised Information Linkage (SAIL) Databank.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.16101","key":"doi250061r11","year":"2018","issue":"4","author":"Ingram","volume":"178","first-page":"917","unstructured":null,"article-title":"Population-based clinical practice research datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.17857","key":"doi250061r12","year":"2022","issue":"5","author":"Kjaersgaard Andersen","volume":"36","first-page":"717","unstructured":null,"article-title":"Incidence and remission rates of self-reported hidradenitis suppurativa—a prospective cohort study conducted in Danish blood donors.","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1159/000536389","key":"doi250061r13","year":"2024","issue":"3","author":"Bouazzi","volume":"240","first-page":"369","unstructured":null,"article-title":"The global hidradenitis suppurativa atlas methodology: combining global proportions in a pooled analysis.","journal-title":"Dermatology","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.21234","key":"doi250061r14","year":"2022","issue":"4","author":"Hagan","volume":"187","first-page":"586","unstructured":null,"article-title":"Prevalence of hidradenitis suppurativa in Berekum, Ghana.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jdin.2020.02.001","key":"doi250061r15","year":"2020","issue":"1","author":"Hagan","volume":"1","first-page":"1","unstructured":null,"article-title":"Hidradenitis suppurativa prevalence in Berekum, Ghana: a cross-sectional study and initial validation of a questionnaire in an African setting.","journal-title":"JAAD Int","doi-asserted-by":"publisher"},{"DOI":"10.1159/000539599","key":"doi250061r16","year":"2024","issue":null,"author":"Chehad","volume":"241","first-page":"9","unstructured":null,"article-title":"Hidradenitis suppurativa prevalence in Algeria: a multicenter cross-sectional study.","journal-title":"Dermatology","doi-asserted-by":"publisher"},{"DOI":"10.1159/000531561","key":"doi250061r17","year":"2023","issue":"5","author":"Anaba","volume":"239","first-page":"832","unstructured":null,"article-title":"Prevalence of hidradenitis suppurativa in an African population: validation of a screening questionnaire in Lagos, Nigeria.","journal-title":"Dermatology","doi-asserted-by":"publisher"},{"DOI":"10.1111/ijd.17454","key":"doi250061r18","year":"2024","issue":"11","author":"Vural","volume":"63","first-page":"e358","unstructured":null,"article-title":"Prevalence of hidradenitis suppurativa in a Turkish population: validation of a screening questionnaire in Istanbul, Turkey.","journal-title":"Int J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2025.2373","key":"doi250061r19","year":"2025","issue":"10","author":"Bouazzi","volume":"161","first-page":"1022","unstructured":null,"article-title":"Prevalence of hidradenitis suppurativa: a meta-analysis of global hidradenitis suppurativa atlas studies.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1159/000539019","key":"doi250061r20","year":"2025","issue":null,"author":"Geng","volume":"241","first-page":"35","unstructured":null,"article-title":"Prevalence of hidradenitis suppurativa in Xi’an, China: a single center epidemiological study.","journal-title":"Dermatology","doi-asserted-by":"publisher"},{"DOI":"10.2340/actadv.v103.4410","key":"doi250061r21","year":"2023","issue":null,"author":"Botvid","volume":"103","first-page":null,"unstructured":null,"article-title":"Hidradenitis suppurativa prevalence in Nuuk, Greenland: Physician Validation of a Hidradenitis Suppurativa Questionnaire in a Greenlandic setting.","journal-title":"Acta Derm Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1177/12034754241303060","key":"doi250061r22","year":"2024","issue":"2","author":"Johnston","volume":"29","first-page":"196","unstructured":null,"article-title":"The prevalence of hidradenitis suppurativa in Calgary, Alberta, Canada: Results from a Participating Site in the Global Hidradenitis Suppurativa Atlas Cross-Sectional Study.","journal-title":"J Cutan Med Surg","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2020.3630","key":"doi250061r23","year":"2020","issue":"12","author":"van Straalen","volume":"156","first-page":"1359","unstructured":null,"article-title":"Contribution of genetics to the susceptibility to hidradenitis suppurativa in a large, cross-sectional Dutch twin cohort.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.20654","key":"doi250061r24","year":"2022","issue":"1","author":"Kjaersgaard Andersen","volume":"186","first-page":"78","unstructured":null,"article-title":"Evidence of gene-gene interaction in hidradenitis suppurativa: a nationwide registry study of Danish twins.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jdermsci.2015.04.003","key":"doi250061r25","year":"2015","issue":"1","author":"Takazawa","volume":"79","first-page":"10","unstructured":null,"article-title":"Notch down-regulation in regenerated epidermis contributes to enhanced expression of interleukin-36a and suppression of keratinocyte differentiation during wound healing.","journal-title":"J Dermatol Sci","doi-asserted-by":"publisher"},{"DOI":"10.1002/stem.2723","key":"doi250061r26","year":"2018","issue":"1","author":"Veltri","volume":"36","first-page":"22","unstructured":null,"article-title":"Concise review: Wnt signaling pathways in skin development and epidermal stem cells.","journal-title":"Stem Cells","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0092-8674(01)00336-1","key":"doi250061r27","year":"2001","issue":"4","author":"Huelsken","volume":"105","first-page":"533","unstructured":null,"article-title":"beta-catenin controls hair follicle morphogenesis and stem cell differentiation in the skin.","journal-title":"Cell","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.stem.2013.10.003","key":"doi250061r28","year":"2013","issue":"6","author":"Choi","volume":"13","first-page":"720","unstructured":null,"article-title":"Distinct functions for Wnt/ß-catenin in hair follicle stem cell proliferation and survival and interfollicular epidermal homeostasis.","journal-title":"Cell Stem Cell","doi-asserted-by":"publisher"},{"DOI":"10.1038/jid.2012.372","key":"doi250061r29","year":"2013","issue":"3","author":"Pink","volume":"133","first-page":"601","unstructured":null,"article-title":"?-Secretase mutations in hidradenitis suppurativa: new insights into disease pathogenesis.","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.12068","key":"doi250061r30","year":"2013","issue":"4","author":"Melnik","volume":"168","first-page":"876","unstructured":null,"article-title":"Impaired notch signalling: the unifying mechanism explaining the pathogenesis of hidradenitis suppurativa (acne inversa).","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.14024","key":"doi250061r31","year":"2015","issue":"5","author":"Tzellos","volume":"173","first-page":"1142","unstructured":null,"article-title":"Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2019.10.044","key":"doi250061r32","year":"2020","issue":"4","author":"Acharya","volume":"82","first-page":"1006","unstructured":null,"article-title":"Hidradenitis suppurativa and smoking: a systematic review and meta-analysis.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1093/ced/llad182","key":"doi250061r33","year":"2023","issue":"9","author":"Mintoff","volume":"48","first-page":"984","unstructured":null,"article-title":"Obesity and hidradenitis suppurativa: targeting meta-inflammation for therapeutic gain.","journal-title":"Clin Exp Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2133.2008.08604.x","key":"doi250061r34","year":"2008","issue":"1","author":"Happle","volume":"159","first-page":"255","unstructured":null,"article-title":"A lesson to be learned from Karl Marx: smoking triggers hidradenitis suppurativa.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1186/s12916-024-03607-5","key":"doi250061r35","year":"2024","issue":"1","author":"Burgess","volume":"22","first-page":"374","unstructured":null,"article-title":"Addressing the credibility crisis in Mendelian randomization.","journal-title":"BMC Med","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2024.6068","key":"doi250061r36","year":"2025","issue":"3","author":"Hettinger","volume":"161","first-page":"328","unstructured":null,"article-title":"Mendelian randomization for dermatology research.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1101/cshperspect.a040501","key":"doi250061r37","year":"2022","issue":"1","author":"Richmond","volume":"12","first-page":null,"unstructured":null,"article-title":"Mendelian randomization: concepts and scope.","journal-title":"Cold Spring Harb Perspect Med","doi-asserted-by":"publisher"},{"DOI":"10.1007/s10552-022-01562-1","key":"doi250061r38","year":"2022","issue":"5","author":"Wade","volume":"33","first-page":"631","unstructured":null,"article-title":"Applying Mendelian randomization to appraise causality in relationships between nutrition and cancer.","journal-title":"Cancer Causes Control","doi-asserted-by":"publisher"},{"DOI":"10.1007/s10654-017-0255-x","key":"doi250061r39","year":"2017","issue":"5","author":"Burgess","volume":"32","first-page":"377","unstructured":null,"article-title":"Interpreting findings from Mendelian randomization using the MR-Egger method.","journal-title":"Eur J Epidemiol","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41467-019-12760-y","key":"doi250061r40","year":"2019","issue":"1","author":"López-Isac","volume":"10","first-page":"4955","unstructured":null,"article-title":"GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways.","journal-title":"Nat Commun","doi-asserted-by":"publisher"},{"DOI":"10.1093/hmg/ddy271","key":"doi250061r41","year":"2018","issue":"20","author":"Yengo","volume":"27","first-page":"3641","unstructured":null,"article-title":"Meta-analysis of genome-wide association studies for height and body mass index in ~700000 individuals of European ancestry.","journal-title":"Hum Mol Genet","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41588-018-0307-5","key":"doi250061r42","year":"2019","issue":"2","author":"Liu","volume":"51","first-page":"237","unstructured":null,"article-title":"Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use.","journal-title":"Nat Genet","doi-asserted-by":"publisher"},{"DOI":"10.1038/ncomms15382","key":"doi250061r43","year":"2017","issue":null,"author":"Tsoi","volume":"8","first-page":"15382","unstructured":null,"article-title":"Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants.","journal-title":"Nat Commun","doi-asserted-by":"publisher"},{"DOI":"10.1038/ng.3359","key":"doi250061r44","year":"2015","issue":"9","author":"Liu","volume":"47","first-page":"979","unstructured":null,"article-title":"Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations.","journal-title":"Nat Genet","doi-asserted-by":"publisher"},{"DOI":"10.1038/ng.3211","key":"doi250061r45","year":"2015","issue":"3","author":"Bulik-Sullivan","volume":"47","first-page":"291","unstructured":null,"article-title":"LD score regression distinguishes confounding from polygenicity in genome-wide association studies.","journal-title":"Nat Genet","doi-asserted-by":"publisher"},{"DOI":"10.1038/nature14177","key":"doi250061r47","year":"2015","issue":"7538","author":"Locke","volume":"518","first-page":"197","unstructured":null,"article-title":"Genetic studies of body mass index yield new insights for obesity biology.","journal-title":"Nature","doi-asserted-by":"publisher"},{"DOI":"10.1007/s00265-012-1416-2","key":"doi250061r48","year":"2012","issue":"11","author":"Dingemanse","volume":"66","first-page":"1543","unstructured":null,"article-title":"Defining behavioural syndromes and the role of ‘syndrome deviation’ in understanding their evolution.","journal-title":"Behav Ecol Sociobiol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamanetworkopen.2024.19029","key":"doi250061r49","year":"2024","issue":"6","author":"Chodick","volume":"7","first-page":null,"unstructured":null,"article-title":"Heritability of body mass index among familial generations.","journal-title":"JAMA Netw Open","doi-asserted-by":"publisher"},{"DOI":"10.1007/s10519-004-1327-8","key":"doi250061r50","year":"2005","issue":"4","author":"Vink","volume":"35","first-page":"397","unstructured":null,"article-title":"Heritability of smoking initiation and nicotine dependence.","journal-title":"Behav Genet","doi-asserted-by":"publisher"},{"DOI":"10.1093/hmg/ddu174","key":"doi250061r51","year":"2014","issue":"17","author":"Chen","volume":"23","first-page":"4710","unstructured":null,"article-title":"Estimation and partitioning of (co)heritability of inflammatory bowel disease from GWAS and immunochip data.","journal-title":"Hum Mol Genet","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.12375","key":"doi250061r52","year":"2013","issue":"2","author":"Lønnberg","volume":"169","first-page":"412","unstructured":null,"article-title":"Heritability of psoriasis in a large twin sample.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaut.2015.07.005","key":"doi250061r53","year":"2015","issue":null,"author":"Bossini-Castillo","volume":"64","first-page":"53","unstructured":null,"article-title":"Immunogenetics of systemic sclerosis: Defining heritability, functional variants and shared-autoimmunity pathways.","journal-title":"J Autoimmun","doi-asserted-by":"publisher"},{"DOI":"10.1093/ije/dyv080","key":"doi250061r54","year":"2015","issue":"2","author":"Bowden","volume":"44","first-page":"512","unstructured":null,"article-title":"Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression.","journal-title":"Int J Epidemiol","doi-asserted-by":"publisher"},{"DOI":"10.1093/ije/dyx034","key":"doi250061r55","year":"2017","issue":"6","author":"Yavorska","volume":"46","first-page":"1734","unstructured":null,"article-title":"Mendelian randomization: an R package for performing Mendelian randomization analyses using summarized data.","journal-title":"Int J Epidemiol","doi-asserted-by":"publisher"},{"DOI":"10.1534/genetics.117.300630","key":"doi250061r57","year":"2018","issue":"3","author":"Sodini","volume":"209","first-page":"941","unstructured":null,"article-title":"Comparison of genotypic and phenotypic correlations: Cheverud’s conjecture in humans.","journal-title":"Genetics","doi-asserted-by":"publisher"},{"DOI":"10.1093/ajcn/nqaa181","key":"doi250061r58","year":"2020","issue":"4","author":"Masip","volume":"112","first-page":"956","unstructured":null,"article-title":"The genetic architecture of the association between eating behaviors and obesity: combining genetic twin modeling and polygenic risk scores.","journal-title":"Am J Clin Nutr","doi-asserted-by":"publisher"},{"DOI":"10.2340/00015555-1800","key":"doi250061r59","year":"2014","issue":"5","author":"Kromann","volume":"94","first-page":"553","unstructured":null,"article-title":"The influence of body weight on the prevalence and severity of hidradenitis suppurativa.","journal-title":"Acta Derm Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.17328","key":"doi250061r60","year":"2024","issue":"10","author":"Luo","volume":"51","first-page":"1335","unstructured":null,"article-title":"Causal relationship between metabolic syndrome and hidradenitis suppurativa: a two-sample bidirectional Mendelian randomization study.","journal-title":"J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.17436","key":"doi250061r61","year":"2025","issue":"1","author":"Wang","volume":"52","first-page":"155","unstructured":null,"article-title":"Association of hidradenitis suppurativa (HS) with waist circumference: a bidirectional two-sample Mendelian randomization study of HS with metabolic syndrome.","journal-title":"J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2020.1281","key":"doi250061r62","year":"2020","issue":"7","author":"Kjærsgaard Andersen","volume":"156","first-page":"780","unstructured":null,"article-title":"Disease trajectories for hidradenitis suppurativa in the Danish population.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2024.3779","key":"doi250061r63","year":"2024","issue":"1","author":"Nielsen","volume":"161","first-page":"22","unstructured":null,"article-title":"Genetic susceptibility to hidradenitis suppurativa and predisposition to cardiometabolic disease.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2008.06.020","key":"doi250061r64","year":"2008","issue":"4","author":"Revuz","volume":"59","first-page":"596","unstructured":null,"article-title":"Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1093/bjd/ljad530","key":"doi250061r65","year":"2024","issue":"6","author":"Kjærsgaard Andersen","volume":"190","first-page":"904","unstructured":null,"article-title":"Initial steps towards developing a predictive algorithm of disease progression for hidradenitis suppurativa: results from a Cox proportional hazard regression analysis on disease progression amongst a cohort of 335 Danish patients with hidradenitis suppurativa.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1159/000539443","key":"doi250061r66","year":"2025","issue":null,"author":"Ibekwe","volume":"241","first-page":"76","unstructured":null,"article-title":"Prevalence of hidradenitis suppurativa among healthy adults in Abuja, Nigeria.","journal-title":"Dermatology","doi-asserted-by":"publisher"},{"DOI":"10.1159/000543025","key":"doi250061r67","year":"2025","issue":null,"author":"Saeed","volume":"241","first-page":"123","unstructured":null,"article-title":"Prevalence of hidradenitis suppurativa in Durban, KwaZulu-Natal South Africa.","journal-title":"Dermatology","doi-asserted-by":"publisher"},{"DOI":"10.1159/000538727","key":"doi250061r68","year":"2025","issue":null,"author":"Binamer","volume":"241","first-page":"112","unstructured":null,"article-title":"Prevalence of hidradenitis suppurativa in Saudi Arabia.","journal-title":"Dermatology","doi-asserted-by":"publisher"},{"DOI":"10.1159/000540156","key":"doi250061r69","year":"2025","issue":null,"author":"Al Maharbi","volume":"241","first-page":"87","unstructured":null,"article-title":"Prevalence of hidradenitis suppurativa in Oman.","journal-title":"Dermatology","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi250061r70","year":"2023","issue":"10","author":"Tolstrup","volume":"70","first-page":null,"unstructured":null,"article-title":"Time trends in body mass index distribution in the general population in Denmark from 1987 to 2021.","journal-title":"Dan Med J","doi-asserted-by":null},{"DOI":"10.1002/gepi.21998","key":"doi250061r76","year":"2016","issue":"7","author":"Burgess","volume":"40","first-page":"597","unstructured":null,"article-title":"Bias due to participant overlap in two-sample Mendelian randomization.","journal-title":"Genet Epidemiol","doi-asserted-by":"publisher"},{"DOI":"10.1038/nature11582","key":"doi250061r77","year":"2012","issue":"7422","author":"Jostins","volume":"491","first-page":"119","unstructured":null,"article-title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.","journal-title":"Nature","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi250061r56","year":"2016","issue":null,"author":"Wickham","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi250061r46","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"BROAD Institute. European LD scores 2023. Accessed May 2023. https://alkesgroup.broadinstitute.org/","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi250061r71","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Eurostat. Body mass index (BMI) by sex, age and educational attainment level 2019. Accessed January 9, 2025. https://ec.europa.eu/eurostat/databrowser/view/HLTH_EHIS_BM1E__custom_6689691/default/table?lang=en&page=time:2019","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi250061r72","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"UK Parliament HoCL. Health Survey for England 2022 2025. Accessed January 9, 2025. https://commonslibrary.parliament.uk/research-briefings/sn03336/","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi250061r73","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Eurostat. Smoking of tobacco products by sex, age and educational attainment level 2019. Accessed January 9, 2025. https://ec.europa.eu/eurostat/databrowser/view/hlth_ehis_sk1e/default/table?lang=en&category=hlth.hlth_det.hlth_smok","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi250061r74","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Census2021. Adult smoking habits in the UK: 2023 2024. Accessed January 9, 2025. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifeexpectancies/bulletins/adultsmokinghabitsingreatbritain/2023","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi250061r75","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Global State of Tobacco Harm Reduction. Tobacco smoking in Denmark 2023. Accessed January 9, 2025. https://gsthr.org/countries/profile/dnk/1/","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"reference-count":77,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,12,17]]},"references-count":77,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1001/jamadermatol.2025.5010","is_oa":true,"title":"Hidradenitis Suppurativa and Smoking, Obesity, Psoriasis, Inflammatory Bowel Disease, and Systemic Sclerosis","updated":"2026-01-13T16:36:47+00:00","published_date":"2025-12-17","best_oa_location":{"url":"https://pure.au.dk/portal/en/publications/aa2f0639-3762-48dd-aff4-c2847d9568b9","pmh_id":"oai:pure.atira.dk:openaire/aa2f0639-3762-48dd-aff4-c2847d9568b9","url_for_pdf":null,"url_for_landing_page":"https://pure.au.dk/portal/en/publications/aa2f0639-3762-48dd-aff4-c2847d9568b9"}}},"created_at":"2026-01-17T09:03:27.421Z","updated_at":"2026-01-17T09:03:27.421Z","tags":[{"paper_doi":"10.1001/jamadermatol.2025.5010","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5010","tag_type":"condition","value":"Hidradenitis Suppurativa","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5010","tag_type":"condition","value":"Inflammatory Bowel Disease","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5010","tag_type":"condition","value":"Psoriasis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5010","tag_type":"condition","value":"Systemic Sclerosis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5010","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5010","tag_type":"study_design","value":"Mendelian Randomization","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5010","tag_type":"warning","value":"Results are from European-ancestry cohorts and may not generalize beyond these populations.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5010","tag_type":"warning","value":"The smoking effect lost robustness in sensitivity analyses, so its causality remains uncertain.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5010","tag_type":"warning","value":"Total sample size varies by GWAS; the HS control count is reported as >1.2 million without an exact number.","value_numeric":null}],"summaries":{"what_studied":"A 2-sample Mendelian randomization tested whether BMI, smoking, psoriasis, inflammatory bowel disease (IBD), and systemic sclerosis (SSc) causally influence hidradenitis suppurativa (HS) using large European-ancestry GWAS (HS: 4,814 cases and >1.2 million controls; exposures up to 1.23 million for smoking). Analyses were conducted in 2024 and updated in 2025.","key_result":"MR supported causal effects of higher BMI (OR per BMI unit 1.20, 95% CI 1.17-1.23; P<.001) and IBD (OR 1.20, 95% CI 1.15-1.24; P<.001) on HS without signs of pleiotropy. Smoking showed a significant estimate (β=0.59; P<.001) but became inconclusive in sensitivity analyses; among IBD, psoriasis, and SSc, only IBD showed support.","limitations":"Findings are limited to White European cohorts, which may affect generalizability. The smoking result was not robust across sensitivity analyses.","practice_takeaway":"Counsel that higher BMI appears causally linked to HS risk; weight management is a reasonable focus. Consider IBD as a causal comorbidity in HS risk discussions, while noting the smoking link remains uncertain."}},{"doi":"10.1111/jdv.70245","pmid":"41392516","title":"Addiction and chronic skin diseases: A Pan‐European study on prevalence, associations and patient impact","journal_title":"Journal of the European Academy of Dermatology and Venereology","journal_issn":"0926-9959","published_at":"2025-12-15T00:00:00.000Z","url":"https://doi.org/10.1111/jdv.70245","source_score":37,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-12-16","doi":"10.1111/jdv.70245","days":"30","issn":"0926-9959","rank":"9","field":"Clinical Medicine","score":"37","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1111/jdv.70245","title":"Addiction and chronic skin diseases: A Pan-European study on prevalence, associations and patient impact.","journal":"Journal of the European Academy of Dermatology and Venereology : JEADV","methods":"","results":"Among 3585 participants (median age 43 years; 51.1% female), the prevalence of addictive behaviours was notable: smoking (25.7%), pathological gambling (4.5%), hazardous drinking (8.8%), alcohol dependence (2.5%), drug use disorders (5.3%), eating disorders (1.8%), and internet addiction (29.7%). Smoking was most common among PSO and HS patients (48.6%), and gambling among AA and vitiligo patients (8.2%). Significant associations included male sex, younger age, single status, higher Dermatology Life Quality Index (DLQI) scores, and regional variation.","abstract":"$37","keywords":["Europe","Hidradenitis Suppurativa","Vitiligo","addictive behaviour","alcohol use","atopic dermatitis","comorbidity","cross‐sectional study","gambling","internet addiction","patient‐reported outcomes","psoriasis","quality of life","skin diseases","stigmatization","urticaria"],"pubmed_id":"41392516","conclusions":"Addiction screening and supportive mental health strategies should be integrated into dermatologic care, particularly for high-risk patients. Population-based studies with control groups are needed to confirm these findings.","publication_date":"2025-12-15T00:00:00"},"crossref":{"DOI":"10.1111/jdv.70245","URL":"https://doi.org/10.1111/jdv.70245","ISSN":["0926-9959","1468-3083"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.70245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Addiction and chronic skin diseases: A Pan‐European study on prevalence, associations and patient impact"],"author":[{"given":"Stefanie","family":"Ziehfreund","sequence":"first","affiliation":[{"name":"Department of Dermatology and Allergy, TUM School of Medicine and Health Technical University of Munich Munich Germany"}]},{"given":"Magdalena","family":"Saak","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, TUM School of Medicine and Health Technical University of Munich Munich Germany"}]},{"given":"Alisa","family":"Schaal","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, TUM School of Medicine and Health Technical University of Munich Munich Germany"}]},{"given":"Roxana","family":"Mazilu","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, TUM School of Medicine and Health Technical University of Munich Munich Germany"}]},{"given":"Emmanuel","family":"Mahé","sequence":"additional","affiliation":[{"name":"Dermatology Department, Centre Hospitalier Victor Dupouy Argenteuil Cedex France"}]},{"given":"Carla","family":"Hajj","sequence":"additional","affiliation":[{"name":"Dermatology Department, Centre Hospitalier Victor Dupouy Argenteuil Cedex France"}]},{"given":"Emma K.","family":"Johansson","sequence":"additional","affiliation":[{"name":"Division of Dermatology and Venereology, Department of Medicine Solna Karolinska Institutet Stockholm Sweden"},{"name":"Department of Dermatology and Venereology Karolinska University Hospital Stockholm Sweden"}]},{"given":"Josefin","family":"Lysell","sequence":"additional","affiliation":[{"name":"Division of Dermatology and Venereology, Department of Medicine Solna Karolinska Institutet Stockholm Sweden"},{"name":"Department of Dermatology and Venereology Karolinska University Hospital Stockholm Sweden"}]},{"given":"Gunnthorunn","family":"Sigurdardottir","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology in Östergötland Linköping University Linköping Sweden"},{"name":"Department of Biomedical and Clinical Sciences Linköping University Linköping Sweden"}]},{"given":"Franz J.","family":"Legat","sequence":"additional","affiliation":[{"name":"Department of Dermatology Medical University of Graz Graz Austria"},{"name":"Das Kurhaus Bad Gleichenberg Bad Gleichenberg Austria"}]},{"given":"Catherina","family":"Koch","sequence":"additional","affiliation":[{"name":"Department of Dermatology Medical University of Graz Graz Austria"}]},{"given":"Astrid","family":"Schmieder","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology University Hospital Würzburg Wurzburg Germany"}]},{"given":"Caroline","family":"Glatzel","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology University Hospital Würzburg Wurzburg Germany"}]},{"given":"Brian","family":"Kirby","sequence":"additional","affiliation":[{"name":"Charles Department of Dermatology, St. Vincent's University Hospital Dublin Ireland"}]},{"given":"Emily","family":"Pender","sequence":"additional","affiliation":[{"name":"Charles Department of Dermatology, St. Vincent's University Hospital Dublin Ireland"}]},{"given":"Anna","family":"Zalewska‐Janowska","sequence":"additional","affiliation":[{"name":"Psychodermatology and Neuroimmunobiology of Skin Department Medical University of Lodz Łódź Poland"}]},{"given":"Katarzyna","family":"Tomaszewska","sequence":"additional","affiliation":[{"name":"Psychodermatology and Neuroimmunobiology of Skin Department Medical University of Lodz Łódź Poland"}]},{"given":"Giulia","family":"Ciccarese","sequence":"additional","affiliation":[{"name":"Unit of Dermatology, Department of Medical and Surgical Sciences University of Foggia Foggia Italy"}]},{"given":"Pia","family":"Lauriola","sequence":"additional","affiliation":[{"name":"Unit of Dermatology, Department of Medical and Surgical Sciences University of Foggia Foggia Italy"}]},{"given":"Michael J.","family":"Boffa","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Mater Dei Hospital Msida Malta"}]},{"given":"Stephanie","family":"Farrugia","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Mater Dei Hospital Msida Malta"}]},{"given":"Anna Caroline","family":"Pilz","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical Center – University of Freiburg, Faculty of Medicine University of Freiburg Freiburg Germany"}]},{"given":"Franziska","family":"Schauer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical Center – University of Freiburg, Faculty of Medicine University of Freiburg Freiburg Germany"}]},{"given":"Magdalena","family":"Trzeciak","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, Faculty of Medicine Medical University of Gdansk Gdansk Poland"},{"name":"Department of Dermatology, Venereology and Allergology University Clinical Center Gdansk Poland"}]},{"given":"Weronika","family":"Zysk","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, Faculty of Medicine Medical University of Gdansk Gdansk Poland"}]},{"given":"Krisztián","family":"Gáspár","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine University of Debrecen Debrecen Hungary"}]},{"given":"Andrea","family":"Szegedi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine University of Debrecen Debrecen Hungary"}]},{"given":"Giovanni","family":"Damiani","sequence":"additional","affiliation":[{"name":"Department of Biomedical, Surgical, and Dental Sciences University of Milan Milan Italy"},{"name":"Italian Centre for Coordinated Research in Precision Medicine and Chronic Inflammation University of Milan Milan Italy"}]},{"given":"Andrea","family":"Carugno","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medicine and Surgery University of Insubria Varese Italy"}]},{"given":"Ilona","family":"Hartmane","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venerology Riga Stradinš University Riga Latvia"}]},{"given":"Ingmars","family":"Mikazans","sequence":"additional","affiliation":[{"name":"Department of Skin and Venereal Diseases Lithuanian University of Health Sciences Kaunas Lithuania"}]},{"given":"Skaidra","family":"Valiukeviciene","sequence":"additional","affiliation":[{"name":"Department of Skin and Venereal Diseases Lithuanian University of Health Sciences Kaunas Lithuania"}]},{"given":"Livija","family":"Petrokaite","sequence":"additional","affiliation":[{"name":"Department of Skin and Venereal Diseases Lithuanian University of Health Sciences Kaunas Lithuania"}]},{"given":"Jacek C.","family":"Szepietowski","sequence":"additional","affiliation":[{"name":"Department of Dermato‐Venerology, 4th Military Hospital Wroclaw Poland"},{"name":"Faculty of Medicine Wroclaw University of Science and Technology Wroclaw Poland"}]},{"given":"Beata","family":"Jastrząb","sequence":"additional","affiliation":[{"name":"University Centre of General Dermatology and Oncodermatology Wroclaw Medical University Wroclaw Poland"}]},{"given":"Petra","family":"Staubach","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Medical Center Mainz Mainz Germany"}]},{"given":"Suzana Ljubojević","family":"Hadžavdić","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Medical Center Mainz Mainz Germany"},{"name":"Department of Dermatology and Venereology University Hospital Center Zagreb Zagreb Croatia"}]},{"given":"Daška Štulhofer","family":"Buzina","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology University Hospital Center Zagreb Zagreb Croatia"}]},{"given":"Christian","family":"Posch","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, TUM School of Medicine and Health Technical University of Munich Munich Germany"},{"name":"Department for Dermatology, Clinic Hietzing Vienna Healthcare Group Vienna Austria"},{"name":"School of Medicine Sigmund Freud University Vienna Austria"}]},{"given":"Jakob","family":"Jochmann","sequence":"additional","affiliation":[{"name":"Department for Dermatology, Clinic Hietzing Vienna Healthcare Group Vienna Austria"}]},{"given":"Antonia","family":"Wiala","sequence":"additional","affiliation":[{"name":"Department for Dermatology and Venereology, Clinic Landstrasse Vienna Healthcare Group Vienna Austria"}]},{"given":"Ludwig","family":"Scheffenbichler","sequence":"additional","affiliation":[{"name":"Department for Dermatology and Venereology, Clinic Donaustadt Vienna Healthcare Group Vienna Austria"}]},{"given":"Emanuele","family":"Trovato","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medical, Surgical and Neurological Sciences University of Siena Siena Italy"}]},{"given":"Laura","family":"Calabrese","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medical, Surgical and Neurological Sciences University of Siena Siena Italy"}]},{"given":"Gyula Laszlo","family":"Fekete","sequence":"additional","affiliation":[{"name":"Dermatology Department, ‘George Emil Palade’ University of Medicine, Pharmacy, Science and Technology Targu Mures Romania"},{"name":"CMI Dermamed Private Medical Office Targu Mures Romania"}]},{"given":"Pavel","family":"Chernyshov","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology National Medical University Kiev Ukraine"}]},{"given":"Lidiia","family":"Kolodzinska","sequence":"additional","affiliation":[{"name":"Khmelnytskyi City Medical and Diagnostic Center, 2nd Polyclinic Khmelnytskyi Ukraine"}]},{"given":"Julia","family":"Welzel","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology Augsburg University Hospital Augsburg Germany"}]},{"given":"Karisa","family":"Thölken","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology Augsburg University Hospital Augsburg Germany"}]},{"given":"Julia‐Tatjana","family":"Maul","sequence":"additional","affiliation":[{"name":"Faculty of Medicine University of Zürich Zurich Switzerland"},{"name":"Department of Dermatology University Hospital of Zurich Zurich Switzerland"},{"name":"Department Dermatology and Venereology University Hospital of Zurich Zurich Switzerland"}]},{"given":"Lara Valeska","family":"Maul","sequence":"additional","affiliation":[{"name":"Faculty of Medicine University of Zürich Zurich Switzerland"},{"name":"Department of Dermatology University Hospital of Zurich Zurich Switzerland"},{"name":"Department Dermatology and Venereology University Hospital of Zurich Zurich Switzerland"}]},{"given":"Damian","family":"Meyersburg","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology University Hospital Salzburg of the Paracelsus Medical University Salzburg Austria"}]},{"given":"Stephanie","family":"Bowe","sequence":"additional","affiliation":[{"name":"Department of Dermatology, South Infirmary Victoria Hospital Cork Ireland"}]},{"given":"Cathal O.","family":"Connor","sequence":"additional","affiliation":[{"name":"Department of Dermatology, South Infirmary Victoria Hospital Cork Ireland"}]},{"given":"Razvigor","family":"Darlenski","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology Trakia University Stara Zagora Bulgaria"}]},{"given":"Stephan","family":"Traidl","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy Hannover Medical School Hannover Germany"}]},{"given":"Christian","family":"Vestergaard","sequence":"additional","affiliation":[{"name":"Department of Dermatology Aarhus University Hospital Aarhus Denmark"}]},{"given":"Elena Lucía","family":"Pinto‐Pulido","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Príncipe de Asturias Madrid Spain"}]},{"given":"Maria Polina","family":"Konstantinou","sequence":"additional","affiliation":[{"name":"Department of Dermatology University General Hospital of Heraklion Heraklion Greece"}]},{"given":"Eszter","family":"Szlávicz","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Oncodermatology, Medical Faculty University of Pécs Pécs Hungary"},{"name":"Archiepiscopal College of Veszprém Veszprém Hungary"}]},{"given":"Kristine","family":"Heidemeyer","sequence":"additional","affiliation":[{"name":"Department of Dermatology Bern University Hospital, University of Bern Inselspital Switzerland"}]},{"given":"Nikhil","family":"Yawalkar","sequence":"additional","affiliation":[{"name":"Department of Dermatology Bern University Hospital, University of Bern Inselspital Switzerland"}]},{"given":"Hanka Agnes Caroline","family":"Lantzsch","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology Asklepios Nordseeklinik Sylt/Westerland Sylt OT Westerland Germany"}]},{"given":"Aleksandra","family":"Soplinska","sequence":"additional","affiliation":[{"name":"Department of Dermatology Medical University of Warsaw Warsaw Poland"}]},{"given":"Anna‐Theresa","family":"Seitz","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venerology and Allergology, Faculty of Medicine Leipzig University Leipzig Germany"}]},{"given":"Tiago","family":"Torres","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Centro Hospitalar Universitário de Santo António University of Porto Porto Portugal"}]},{"given":"Zenon","family":"Brzoza","sequence":"additional","affiliation":[{"name":"Department of Internal Diseases with Division of Allergology University of Opole Opole Poland"}]},{"given":"Ana Sanader","family":"Vučemilović","sequence":"additional","affiliation":[{"name":"Department of Dermatovenerology University Hospital Centre Split Split Croatia"}]},{"given":"Liana","family":"Manolache","sequence":"additional","affiliation":[{"name":"Dermatology, Dali Medical Bucharest Romania"}]},{"given":"Nina","family":"Magnolo","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital of Muenster Münster Germany"}]},{"given":"Emanuele","family":"Scala","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Immunology, Istituto Dermopatico dell'Immacolata‐Istituto di Ricovero e Cura a Carattere Scientifico (IDI‐IRCCS) Rome Italy"}]},{"given":"Kilian","family":"Eyerich","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical Center – University of Freiburg, Faculty of Medicine University of Freiburg Freiburg Germany"}]},{"given":"Tilo","family":"Biedermann","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, TUM School of Medicine and Health Technical University of Munich Munich Germany"}]},{"given":"Alexander","family":"Zink","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, TUM School of Medicine and Health Technical University of Munich Munich Germany"},{"name":"Department of Dermatology, Medical Center – University of Freiburg, Faculty of Medicine University of Freiburg Freiburg Germany"}]}],"funder":[{"id":[{"id":"10.13039/501100021201","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100021201","name":"European Academy of Dermatology and Venereology","award":["PPRC‐2022‐19"],"award-info":[{"award-number":["PPRC‐2022‐19"]}],"doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2025,12,14]]},"member":"311","prefix":"10.1111","source":"Crossref","volume":null,"archive":["Portico"],"created":{"date-time":"2025-12-15T06:47:20Z","timestamp":1765781240000,"date-parts":[[2025,12,15]]},"indexed":{"date-time":"2025-12-15T06:50:41Z","timestamp":1765781441489,"date-parts":[[2025,12,15]]},"license":[{"URL":"http://creativecommons.org/licenses/by/4.0/","start":{"date-time":"2025-12-14T00:00:00Z","timestamp":1765670400000,"date-parts":[[2025,12,14]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":"$38","language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1111/jdv.70245"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-01-22"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-10-29"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2025-12-14"}],"deposited":{"date-time":"2025-12-15T06:47:22Z","timestamp":1765781242000,"date-parts":[[2025,12,15]]},"issn-type":[{"type":"print","value":"0926-9959"},{"type":"electronic","value":"1468-3083"}],"published":{"date-parts":[[2025,12,14]]},"publisher":"Wiley","reference":[{"DOI":"10.1038/jid.2013.446","key":"e_1_2_14_2_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.15494","key":"e_1_2_14_3_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3238/arztebl.m2024.0064","key":"e_1_2_14_4_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2147/PTT.S328572","key":"e_1_2_14_5_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaci.2022.12.002","key":"e_1_2_14_6_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s13555‐023‐01001‐2","key":"e_1_2_14_7_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/jcm9061818","key":"e_1_2_14_8_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.14204","key":"e_1_2_14_9_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.17708","key":"e_1_2_14_10_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2147/ptt.S164104","key":"e_1_2_14_11_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_14_12_1","year":"2016","issue":"6","author":"Ferreira BI","volume":"9","first-page":"36","unstructured":null,"article-title":"Psoriasis and associated psychiatric disorders: a systematic review on etiopathogenesis and clinical correlation","journal-title":"J Clin Aesthet Dermatol","doi-asserted-by":null},{"DOI":"10.1111/jdv.14460","key":"e_1_2_14_13_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_14_14_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"WeckerH SvedbomA Sanchez OrregoF ZiehfreundS StahleM ZahA.Assessing the comorbidity cycle between psoriasis and addiction in the Stockholm Psoriasis Cohort.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1007/s00403‐024‐02841‐4","key":"e_1_2_14_15_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1684/ejd.2021.4146","key":"e_1_2_14_16_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346‐8138.15740","key":"e_1_2_14_17_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_14_18_1","year":"2006","issue":"1","author":"Montoya ID","volume":"25","first-page":null,"unstructured":null,"article-title":"Treatment compliance in patients with co‐occurring mental illness and substance abuse","journal-title":"Psychiatr Times","doi-asserted-by":null},{"DOI":"10.1017/s1092852918001426","key":"e_1_2_14_19_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2340/00015555‐1188","key":"e_1_2_14_20_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1172/jci172883","key":"e_1_2_14_21_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/jamanetworkopen.2023.7888","key":"e_1_2_14_22_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.15497","key":"e_1_2_14_23_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1186/s12877‐023‐03972‐5","key":"e_1_2_14_24_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/s2468‐2667(24)00126‐9","key":"e_1_2_14_25_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s00406‐024‐01778‐z","key":"e_1_2_14_26_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365‐2230.1994.tb01167.x","key":"e_1_2_14_27_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_14_28_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Survey ES.Dimensions of Wellbeing.https://www.europeansocialsurvey.org/findings/europeans‐wellbeing/dimensions‐wellbeing.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.2466/pr0.95.3.1009‐1013","key":"e_1_2_14_29_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1360-0443.1993.tb02093.x","key":"e_1_2_14_30_1","year":"1993","issue":"6","author":"Saunders B","volume":"88","first-page":"791","unstructured":null,"article-title":"Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption II","journal-title":"Addiction","doi-asserted-by":"crossref"},{"DOI":"10.1159/000081413","key":"e_1_2_14_31_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jsat.2015.01.008","key":"e_1_2_14_32_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/erv.2515","key":"e_1_2_14_33_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1089/cpb.2004.7.443","key":"e_1_2_14_34_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1371/journal.pone.0137506","key":"e_1_2_14_35_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_14_36_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Division UNS.United Nations Geoscheme for Europe https://unstats.un.org/unsd/methodology/m49/.1999.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1007/978-1-4614-1353-0","key":"e_1_2_14_37_1","year":"2012","issue":null,"author":"Vittinghoff E","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":null,"key":"e_1_2_14_38_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Eurostat.Daily smokers of cigarettes by sex age and educational attainment level.https://ec.europa.eu/eurostat/databrowser/view/hlth_ehis_sk3e__custom_13143640/default/table?lang=en&page=time:20192024.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2019.10.044","key":"e_1_2_14_39_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1177/0300060520964024","key":"e_1_2_14_40_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2016.07.017","key":"e_1_2_14_41_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1600‐0625.2008.00712_1.x","key":"e_1_2_14_42_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2016.07.041","key":"e_1_2_14_43_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.addbeh.2021.107115","key":"e_1_2_14_44_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1097/yco.0000000000000278","key":"e_1_2_14_45_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/socsci13060305","key":"e_1_2_14_46_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3233/wor‐211281","key":"e_1_2_14_47_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1556/2006.2024.00049","key":"e_1_2_14_48_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2340/actadv.v103.9378","key":"e_1_2_14_49_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.18977","key":"e_1_2_14_50_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.5812/ijpbs.109103","key":"e_1_2_14_51_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2340/00015555‐0246","key":"e_1_2_14_52_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.19567","key":"e_1_2_14_53_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.17348","key":"e_1_2_14_54_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s10899‐024‐10361‐z","key":"e_1_2_14_55_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1159/000528945","key":"e_1_2_14_56_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.17833","key":"e_1_2_14_57_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s00403‐024‐03189‐5","key":"e_1_2_14_58_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2022.0248","key":"e_1_2_14_59_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1111/jdv.70245"],"article-number":"jdv.70245","content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"reference-count":58,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,12,14]]},"references-count":58,"short-container-title":["Acad Dermatol Venereol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1111/jdv.70245","is_oa":true,"title":"Addiction and chronic skin diseases: A Pan‐European study on prevalence, associations and patient impact","updated":"2025-12-16T00:51:53+00:00","published_date":"2025-12-14","best_oa_location":{"url":"https://doi.org/10.1111/jdv.70245","pmh_id":null,"url_for_pdf":null,"url_for_landing_page":"https://doi.org/10.1111/jdv.70245"}}},"created_at":"2026-01-11T11:19:33.869Z","updated_at":"2026-01-15T20:51:27.064Z","tags":[{"paper_doi":"10.1111/jdv.70245","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1111/jdv.70245","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/jdv.70245","tag_type":"condition","value":"Alopecia Areata","value_numeric":null},{"paper_doi":"10.1111/jdv.70245","tag_type":"condition","value":"Atopic Dermatitis","value_numeric":null},{"paper_doi":"10.1111/jdv.70245","tag_type":"condition","value":"Hidradenitis Suppurativa","value_numeric":null},{"paper_doi":"10.1111/jdv.70245","tag_type":"condition","value":"Psoriasis","value_numeric":null},{"paper_doi":"10.1111/jdv.70245","tag_type":"condition","value":"Urticaria","value_numeric":null},{"paper_doi":"10.1111/jdv.70245","tag_type":"condition","value":"Vitiligo","value_numeric":null},{"paper_doi":"10.1111/jdv.70245","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1111/jdv.70245","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1111/jdv.70245","tag_type":"sample_size","value":"n=3585","value_numeric":3585},{"paper_doi":"10.1111/jdv.70245","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1111/jdv.70245","tag_type":"study_design","value":"Cross-Sectional Study","value_numeric":null},{"paper_doi":"10.1111/jdv.70245","tag_type":"warning","value":"Design classification and outcomes are based on the abstract; full methods were not reviewed.","value_numeric":null},{"paper_doi":"10.1111/jdv.70245","tag_type":"warning","value":"Subgroup rates (e.g., 48.6% for smoking in PSO/HS and 8.2% for gambling in AA/vitiligo) lack clear denominators and may combine conditions.","value_numeric":null}],"summaries":{"what_studied":"A multicentre cross-sectional survey in tertiary dermatology centres across 20 European countries assessed addictive behaviours among adults with psoriasis, atopic dermatitis, hidradenitis suppurativa, alopecia areata, urticaria, or vitiligo (n=3585; median age 43; 51.1% female). Standardized questionnaires captured sociodemographics, disease features, DLQI, and addictions; multivariable logistic regression examined associated factors.","key_result":"Prevalence was: smoking 25.7%, pathological gambling 4.5%, hazardous drinking 8.8%, alcohol dependence 2.5%, drug use disorders 5.3%, eating disorders 1.8%, and internet addiction 29.7%. Smoking was most common in psoriasis/hidradenitis (48.6%) and gambling in alopecia areata/vitiligo (8.2%); male sex, younger age, single status, higher DLQI, and region were associated with multiple addictions.","limitations":"No control group and tertiary-care sampling with limited centre distribution and unknown response rate limit generalizability. Disease-specific subgroup denominators were not provided in detail.","practice_takeaway":"Integrate addiction screening and mental health support into dermatologic care, prioritizing high‑risk patients (men, younger, single, higher DLQI). Population-based studies with control groups are needed before applying these rates to all patients."}},{"doi":"10.1001/jamadermatol.2025.4700","pmid":"41296349","title":"Hidradenitis Suppurativa Remission and Progression in a Community Setting","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2025-11-26T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2025.4700","source_score":26,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-11-27","doi":"10.1001/jamadermatol.2025.4700","days":"14","issn":"2168-6068","rank":"3","field":"Clinical Medicine","score":"26","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2025.4700","title":"Hidradenitis Suppurativa Remission and Progression in a Community Setting.","journal":"JAMA dermatology","methods":"","results":"The analysis included 107 patients with HS (mean [SD] age, 47.1 [8.8] years; 88 female [82.2%] and 19 male [17.8%] individuals). At baseline, 57 patients (53.3%) had mild, 20 (18.7%) had moderate, and 30 (28.0%) had severe disease. During the follow-up period, 16.9% of patients with nonsevere disease progressed (13.0% to severe disease), while 71.0% of all patients experienced regression (63.6% to full remission). Stratified by baseline severity, 73.7%, 60.0%, and 46.7% of patients with mild, moderate, and severe disease, respectively, experienced full remission. Cox regression analyses did not reveal any baseline demographic factors capable of predicting disease development at follow-up.","abstract":"$39","keywords":[],"pubmed_id":"41296349","conclusions":"","publication_date":"2025-11-26T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2025.4700","URL":"https://doi.org/10.1001/jamadermatol.2025.4700","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2841755/jamadermatology_kjrsgaard_andersen_2025_br_250012_1763325634.70655.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Hidradenitis Suppurativa Remission and Progression in a Community Setting"],"author":[{"given":"Rune","family":"Kjærsgaard Andersen","sequence":"first","affiliation":[{"name":"PHOENIX Research Center, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen University Hospitals, Gentofte, Denmark"},{"name":"Department of Immunology and Microbiology, Skin Immunology Research Center, University of Copenhagen, Copenhagen, Denmark"},{"name":"Department of Dermatology, Zealand University Hospital, Roskilde, Denmark"}]},{"given":"Morten Kranker","family":"Larsen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Zealand University Hospital, Roskilde, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}]},{"given":"Ole Birger V.","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"Department of Clinical Immunology, Zealand University Hospital, Køge, Denmark"}]},{"given":"Liv","family":"Eidsmo","sequence":"additional","affiliation":[{"name":"Department of Immunology and Microbiology, Skin Immunology Research Center, University of Copenhagen, Copenhagen, Denmark"},{"name":"Division of DermatoVenerology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden"},{"name":"Medicinsk enhet Gastro, Hud, Reuma, Karolinska University Hospital, Stockholm, Sweden"}]},{"given":"Gregor B. E.","family":"Jemec","sequence":"additional","affiliation":[{"name":"PHOENIX Research Center, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen University Hospitals, Gentofte, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}]},{"given":"Christina","family":"Ellervik","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"Department of Clinical Biochemistry, Zealand University Hospital, Køge, Denmark"},{"name":"Department of Laboratory Medicine, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts"}]},{"given":"Ditte M. L.","family":"Saunte","sequence":"additional","affiliation":[{"name":"PHOENIX Research Center, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen University Hospitals, Gentofte, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}]}],"issued":{"date-parts":[[2025,11,26]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":null,"created":{"date-time":"2025-11-26T16:31:35Z","timestamp":1764174695000,"date-parts":[[2025,11,26]]},"indexed":{"date-time":"2025-11-26T16:36:35Z","timestamp":1764174995009,"date-parts":[[2025,11,26]]},"subject":[],"abstract":"$3a","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2841755"}},"subtitle":[],"deposited":{"date-time":"2025-11-26T16:31:37Z","timestamp":1764174697000,"date-parts":[[2025,11,26]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2025,11,26]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1056/NEJMcp1014163","key":"dbr250012r1","year":"2012","issue":"2","author":"Jemec","volume":"366","first-page":"158","unstructured":null,"article-title":"Clinical practice-hidradenitis suppurativa.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1093/bjd/ljad530","key":"dbr250012r2","year":"2024","issue":null,"author":"Kjærsgaard Andersen","volume":null,"first-page":null,"unstructured":null,"article-title":"Initial steps towards developing a predictive algorithm of disease progression for hidradenitis suppurativa: results from a Cox proportional hazard regression analysis on disease progression amongst a cohort of 335 Danish patients with hidradenitis suppurativa.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2025.2373","key":"dbr250012r3","year":"2025","issue":null,"author":"Bouazzi","volume":null,"first-page":null,"unstructured":null,"article-title":"Prevalence of hidradenitis suppurativa: a meta-analysis of Global Hidradenitis Suppurativa Atlas Studies.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2013.11.014","key":"dbr250012r4","year":"2014","issue":"4","author":"Gold","volume":"70","first-page":"699","unstructured":null,"article-title":"The prevalence of metabolic syndrome in patients with hidradenitis suppurativa.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/ced.14478","key":"dbr250012r5","year":"2021","issue":"3","author":"Özkur","volume":"46","first-page":"532","unstructured":null,"article-title":"Clinical and demographic features of hidradenitis suppurativa: a multicentre study of 1221 patients with an analysis of risk factors associated with disease severity.","journal-title":"Clin Exp Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.17857","key":"dbr250012r6","year":"2022","issue":"5","author":"Kjaersgaard Andersen","volume":"36","first-page":"717","unstructured":null,"article-title":"Incidence and remission rates of self-reported hidradenitis suppurativa-a prospective cohort study conducted in Danish blood donors.","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1159/000508787","key":"dbr250012r7","year":"2020","issue":"5","author":"Kokolakis","volume":"236","first-page":"421","unstructured":null,"article-title":"Delayed diagnosis of hidradenitis suppurativa and its effect on patients and healthcare system.","journal-title":"Dermatology","doi-asserted-by":"publisher"},{"DOI":null,"key":"dbr250012r8","year":"2013","issue":"9","author":"Bergholdt","volume":"60","first-page":"A4693","unstructured":null,"article-title":"Study design, participation and characteristics of the Danish General Suburban Population Study.","journal-title":"Dan Med J","doi-asserted-by":null},{"DOI":"10.1111/bjd.15778","key":"dbr250012r9","year":"2018","issue":"1","author":"Juhl","volume":"178","first-page":"222","unstructured":null,"article-title":"Hidradenitis suppurativa and electrocardiographic changes: a cross-sectional population study.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.12787","key":"dbr250012r11","year":"2014","issue":"4","author":"Vinding","volume":"170","first-page":"884","unstructured":null,"article-title":"The prevalence of inverse recurrent suppuration: a population-based study of possible hidradenitis suppurativa.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2014.1165","key":"dbr250012r12","year":"2014","issue":"12","author":"Miller","volume":"150","first-page":"1273","unstructured":null,"article-title":"Association of metabolic syndrome and hidradenitis suppurativa.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.13090","key":"dbr250012r13","year":"2014","issue":"4","author":"Kromann","volume":"171","first-page":"819","unstructured":null,"article-title":"Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.14038","key":"dbr250012r14","year":"2015","issue":"6","author":"Saunte","volume":"173","first-page":"1546","unstructured":null,"article-title":"Diagnostic delay in hidradenitis suppurativa is a global problem.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"dbr250012r10","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Kjærsgaard Andersen? R, Larsen? MK, Pedersen? OBV, . Danish questionnaire for the The Danish General Suburban Population Study (GESUS) follow-up study on hidradenitis suppurativa prevalence and disease development. Accessed November 4, 2025. Mendeley Data, V3. doi:10.17632/j6szpjxtw5.3","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"reference-count":14,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,11,26]]},"references-count":14,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1001/jamadermatol.2025.4700","is_oa":false,"title":"Hidradenitis Suppurativa Remission and Progression in a Community Setting","updated":"2025-11-27T02:22:14+00:00","published_date":"2025-11-26","best_oa_location":null}},"created_at":"2025-11-30T07:03:02.464Z","updated_at":"2025-12-02T07:03:10.886Z","tags":[{"paper_doi":"10.1001/jamadermatol.2025.4700","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4700","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4700","tag_type":"condition","value":"Hidradenitis Suppurativa","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4700","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4700","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4700","tag_type":"sample_size","value":"n=107","value_numeric":107},{"paper_doi":"10.1001/jamadermatol.2025.4700","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4700","tag_type":"study_design","value":"Prospective Cohort Study","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4700","tag_type":"warning","value":"Comparisons to hospital cohorts are contextual; no direct head-to-head comparison was performed.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4700","tag_type":"warning","value":"Findings come from a single Danish municipality cohort, which may limit generalizability.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4700","tag_type":"warning","value":"Progression among “nonsevere” cases is reported as percentages without the exact denominator stated.","value_numeric":null}],"summaries":{"what_studied":"A prospective community-based cohort in Denmark with ~10-year follow-up (baseline 2010–2013; follow-up Jan–Feb 2023) evaluated hidradenitis suppurativa severity transitions using a modified Hurley score and assessed whether baseline variables predicted remission or progression via Cox regression.","key_result":"Among 107 participants, 16.9% with nonsevere disease progressed (13.0% to severe). Overall, 71.0% regressed and 63.6% achieved full remission; remission by baseline severity was 73.7% (mild), 60.0% (moderate), and 46.7% (severe). No baseline demographic predictors of disease development were identified.","limitations":"Single municipality-based Danish cohort identified via questionnaire; small sample size (n=107).","practice_takeaway":"In a community setting, HS showed high rates of regression and remission over a decade and far fewer progressed to severe disease than hospital cohorts report; set expectations accordingly, as baseline demographics did not predict course."}},{"doi":"10.1001/jamadermatol.2025.4652","pmid":"41296358","title":"Standardization of Lesion Classification and Assessment by Investigators in Clinical Trials for Hidradenitis Suppurativa","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2025-11-26T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2025.4652","source_score":2,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-11-27","doi":"10.1001/jamadermatol.2025.4652","days":"7","issn":"2168-6068","rank":"10","field":"Clinical Medicine","score":"2","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2025.4652","title":"Standardization of Lesion Classification and Assessment by Investigators in Clinical Trials for Hidradenitis Suppurativa: A Consensus Exercise Using a Modified Delphi Approach.","journal":"JAMA dermatology","methods":"","results":"","abstract":"$3b","keywords":[],"pubmed_id":"41296358","conclusions":"","publication_date":"2025-11-26T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2025.4652","URL":"https://doi.org/10.1001/jamadermatol.2025.4652","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2841754/jamadermatology_garg_2025_cs_250004_1763325632.7339.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Standardization of Lesion Classification and Assessment by Investigators in Clinical Trials for Hidradenitis Suppurativa"],"author":[{"given":"Amit","family":"Garg","sequence":"first","affiliation":[{"name":"Northwell, New Hyde Park, New York"}]},{"given":"Andrew","family":"Strunk","sequence":"additional","affiliation":[{"name":"Northwell, New Hyde Park, New York"}]},{"given":"Bria","family":"Midgette","sequence":"additional","affiliation":[{"name":"Northwell, New Hyde Park, New York"}]},{"given":"Kelly","family":"Frasier","sequence":"additional","affiliation":[{"name":"Northwell, New Hyde Park, New York"}]},{"given":"Erica","family":"Cohn","sequence":"additional","affiliation":[{"name":"Northwell, New Hyde Park, New York"}]},{"given":"Pim","family":"Aarts","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Erasmus University Medical Center, Rotterdam, the Netherlands"}]},{"given":"Afsaneh","family":"Alavi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Mayo Clinic, Rochester, Minnesota"}]},{"given":"Raed","family":"Alhusayen","sequence":"additional","affiliation":[{"name":"Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada"}]},{"given":"Bitte Falk G.","family":"Bechara","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital of the RWTH Aachen University, Aachen, Germany"}]},{"given":"Vincenzo","family":"Bettoli","sequence":"additional","affiliation":[{"name":"O.U. Dermatology, Azienda Ospedaliera, University of Ferrara, Ferrara, Italy"}]},{"given":"Alain","family":"Brassard","sequence":"additional","affiliation":[{"name":"University of California Davis, Sacramento"}]},{"given":"Debra P.","family":"Brown","sequence":"additional","affiliation":[{"name":"Medical Ethics, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom"}]},{"given":"Nisha Suyien","family":"Chandran","sequence":"additional","affiliation":[{"name":"National Skin Centre, Singapore"}]},{"given":"Siew Eng","family":"Choon","sequence":"additional","affiliation":[{"name":"Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Malaysia"}]},{"given":"Steven R.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Weill Cornell Medical College, New York, New York"}]},{"given":"Steven","family":"Daveluy","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wayne State University School of Medicine, Detroit, Michigan"}]},{"given":"Veronique","family":"del Marmol","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Université Libre de Bruxelles, Brussels, Belgium"}]},{"given":"Robert P.","family":"Dellavalle","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Minnesota, Minneapolis"}]},{"given":"Lennart","family":"Emtestam","sequence":"additional","affiliation":[{"name":"Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden"}]},{"given":"Benhadou","family":"Farida","sequence":"additional","affiliation":[{"name":"Hôpital Universitaire de Bruxelles, Brussels, Belgium"}]},{"given":"Pablo","family":"Fernandez-Penas","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The University of Sydney, Westmead Hospital, Westmead, Australia"}]},{"given":"R. Hal","family":"Flowers","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Virginia, Charlottesville"}]},{"given":"John W.","family":"Frew","sequence":"additional","affiliation":[{"name":"University of New South Wales, Sydney, Australia"}]},{"given":"Kurt A.","family":"Gebauer","sequence":"additional","affiliation":[{"name":"Fremantle Dermatology, Fremantle, Australia"}]},{"given":"Evangelos J.","family":"Giamarellos-Bourboulis","sequence":"additional","affiliation":[{"name":"4th Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece"}]},{"given":"Noah","family":"Goldfarb","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Minnesota, Minneapolis"}]},{"given":"Barbara","family":"Horváth","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen, University of Groningen, Groningen, the Netherlands"}]},{"given":"Jennifer L.","family":"Hsiao","sequence":"additional","affiliation":[{"name":"Keck School of Medicine, University of Southern California, Los Angeles"}]},{"given":"Gregor","family":"Jemec","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Zealand University Hospital, Roskilde, Denmark"}]},{"given":"Michelle A.","family":"Lowes","sequence":"additional","affiliation":[{"name":"The Rockefeller University, New York, New York"}]},{"given":"Angelo V.","family":"Marzano","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy"},{"name":"Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy"}]},{"given":"Lukasz","family":"Matusiak","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology, and Clinical Immunology, Faculty of Medicine, Wroclaw, Poland"}]},{"given":"Robert G.","family":"Micheletti","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pennsylvania, Philadelphia"},{"name":"Department of Medicine, University of Pennsylvania, Philadelphia"},{"name":"Images in Dermatology, JAMA Dermatology"}]},{"given":"Hazel H.","family":"Oon","sequence":"additional","affiliation":[{"name":"National Skin Centre, Lee Kong Chian School of Medicine and Yong Loo Lin School of Medicine, National University of Singapore, Singapore"}]},{"given":"Lauren A. V.","family":"Orenstein","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia"}]},{"given":"Alex G.","family":"Ortega-Loayza","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Oregon Health & Science University, Portland"}]},{"given":"So Yeon","family":"Paek","sequence":"additional","affiliation":[{"name":"Baylor Scott & White, Dallas, Texas"}]},{"given":"Jose C.","family":"Pascual","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Dr Balmis General University Hospital, ISABIAL, Alicante, Spain"}]},{"given":"Vincent","family":"Piguet","sequence":"additional","affiliation":[{"name":"University of Toronto, Toronto, Ontario, Canada"}]},{"given":"Barry I.","family":"Resnik","sequence":"additional","affiliation":[{"name":"Resnik Skin Institute, Miami, Florida"}]},{"given":"David","family":"Rosmarin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Indiana University School of Medicine, Indianapolis"}]},{"given":"Gretchen M.","family":"Roth","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milwaukee"}]},{"given":"Christopher J.","family":"Sayed","sequence":"additional","affiliation":[{"name":"University of North Carolina at Chapel Hill School of Medicine, Chapel Hill"}]},{"given":"Dimitri Luz Felipe","family":"Silva","sequence":"additional","affiliation":[{"name":"Dermco, Perth, Australia"},{"name":"Department of Dermatology, University of Santo Amaro (Unisa), São Paulo, Brazil"}]},{"given":"Linnea","family":"Thorlacius","sequence":"additional","affiliation":[{"name":"Zealand University Hospital and Parker Institute, Copenhagen, Denmark"}]},{"given":"Thrasyvoulos","family":"Tzellos","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital of North Norway, Tromsø, Norway"}]},{"given":"Hessel","family":"van der Zee","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Erasmus University Medical Center, Rotterdam, the Netherlands"}]},{"given":"Kelsey","family":"van Straalen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Erasmus University Medical Center, Rotterdam, the Netherlands"}]},{"given":"John R.","family":"Ingram","sequence":"additional","affiliation":[{"name":"Division of Infection & Immunity, Cardiff University, Cardiff, United Kingdom"}]}],"issued":{"date-parts":[[2025,11,26]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":null,"created":{"date-time":"2025-11-26T16:31:41Z","timestamp":1764174701000,"date-parts":[[2025,11,26]]},"indexed":{"date-time":"2025-11-26T16:36:33Z","timestamp":1764174993572,"date-parts":[[2025,11,26]]},"subject":[],"abstract":"$3c","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2841754"}},"subtitle":["A Consensus Exercise Using a Modified Delphi Approach"],"deposited":{"date-time":"2025-11-26T16:31:42Z","timestamp":1764174702000,"date-parts":[[2025,11,26]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2025,11,26]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1001/jamadermatol.2019.0164","key":"dcs250004r1","year":"2019","issue":"7","author":"Reddy","volume":"155","first-page":"797","unstructured":null,"article-title":"Comparative overall comorbidity burden among patients with hidradenitis suppurativa.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2019.06.016","key":"dcs250004r2","year":"2019","issue":"4","author":"Reddy","volume":"81","first-page":"937","unstructured":null,"article-title":"All-cause mortality among patients with hidradenitis suppurativa: a population-based cohort study in the United States.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(24)02475-9","key":"dcs250004r3","year":"2025","issue":"10476","author":"Sabat","volume":"405","first-page":"420","unstructured":null,"article-title":"Hidradenitis suppurativa.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2025.1976","key":"dcs250004r4","year":"2025","issue":"9","author":"Garg","volume":"161","first-page":"931","unstructured":null,"article-title":"Efficacy and safety of medical interventions for moderate to severe hidradenitis suppurativa: a living systematic review and network meta-analysis.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2019.06.1301","key":"dcs250004r5","year":"2020","issue":"2","author":"Garg","volume":"82","first-page":"366","unstructured":null,"article-title":"Evaluating patients’ unmet needs in hidradenitis suppurativa: results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.21798","key":"dcs250004r6","year":"2022","issue":"6","author":"Midgette","volume":"187","first-page":"927","unstructured":null,"article-title":"Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1093/bjd/ljae379","key":"dcs250004r7","year":"2025","issue":"3","author":"Midgette","volume":"192","first-page":"535","unstructured":null,"article-title":"Intra-rater agreement of lesion counts in hidradenitis suppurativa.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.17716","key":"dcs250004r8","year":"2019","issue":"3","author":"Thorlacius","volume":"181","first-page":"483","unstructured":null,"article-title":"Inter-rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1093/bjd/ljae318","key":"dcs250004r9","year":"2025","issue":null,"author":"Sayed","volume":"192","first-page":"i15","unstructured":null,"article-title":"An evolutionary tale on clinical trials in hidradenitis suppurativa.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.16672","key":"dcs250004r10","year":"2018","issue":"3","author":"Thorlacius","volume":"179","first-page":"642","unstructured":null,"article-title":"A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.21236","key":"dcs250004r12","year":"2022","issue":"2","author":"Garg","volume":"187","first-page":"203","unstructured":null,"article-title":"Development and initial validation of the HS-IGA: a novel hidradenitis suppurativa-specific investigator global assessment for use in interventional trials.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2023.0797","key":"dcs250004r13","year":"2023","issue":"6","author":"Garg","volume":"159","first-page":"606","unstructured":null,"article-title":"Validation of the Hidradenitis Suppurativa Investigator Global Assessment: a novel hidradenitis suppurativa-specific investigator global assessment for use in interventional trials.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.19565","key":"dcs250004r14","year":"2021","issue":"5","author":"Goldfarb","volume":"184","first-page":"905","unstructured":null,"article-title":"Hidradenitis Suppurativa Area and Severity Index Revised (HASI-R): psychometric property assessment.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1371/journal.pmed.1004326","key":"dcs250004r16","year":"2024","issue":"1","author":"Gattrell","volume":"21","first-page":null,"unstructured":null,"article-title":"ACCORD (ACcurate COnsensus Reporting Document): a reporting guideline for consensus methods in biomedicine developed via a modified Delphi.","journal-title":"PLoS Med","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2020.5467","key":"dcs250004r17","year":"2021","issue":"4","author":"Frew","volume":"157","first-page":"449","unstructured":null,"article-title":"Global harmonization of morphological definitions in hidradenitis suppurativa for a proposed glossary.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"dcs250004r11","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"The CHORD COUSIN Collaboratio. HiSTORIC: Hidradenitis Suppurativa Core Outcomes Set International Collaboration: Disease state: hidradenitis suppurativa. Accessed July 17, 2025. https://www.c3outcomes.org/historic","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"dcs250004r15","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"CHORD COUSIN Collaboration. Homepage. Accessed July 17, 2025. https://www.c3outcomes.org","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"reference-count":17,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,11,26]]},"references-count":17,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1001/jamadermatol.2025.4652","is_oa":false,"title":"Standardization of Lesion Classification and Assessment by Investigators in Clinical Trials for Hidradenitis Suppurativa","updated":"2025-11-27T02:22:14+00:00","published_date":"2025-11-26","best_oa_location":null}},"created_at":"2025-12-02T07:03:10.886Z","updated_at":"2025-12-02T07:03:10.886Z","tags":[{"paper_doi":"10.1001/jamadermatol.2025.4652","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4652","tag_type":"condition","value":"Hidradenitis Suppurativa","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4652","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4652","tag_type":"level_of_evidence","value":"7","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4652","tag_type":"study_design","value":"Delphi Consensus Study","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4652","tag_type":"warning","value":"Findings reflect a consensus methodology rather than clinical outcome data.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4652","tag_type":"warning","value":"Only the abstract was available; full definitions and guidance details were not provided here.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4652","tag_type":"warning","value":"Total unique number of participants across rounds is unclear (denominators vary: 59, 50, 44).","value_numeric":null}],"summaries":{"what_studied":"A preliminary image-based survey followed by a 2-round electronic Delphi process sought consensus morphological definitions and guidance for investigator assessment of hidradenitis suppurativa lesions in clinical trials. Participants were health professionals (primarily dermatologists) with HS measurement expertise and novice raters.","key_result":"Response rates were 84.7% (50/59) for the preliminary survey, 86.0% (43/50) for Delphi round 1, and 90.9% (40/44) for round 2. Consensus (≥70%) was reached for 11 lesion-type definitions (9 with ≥90% agreement) and for 16/18 guidance statements (13 with >80% endorsement); no consensus was reached for assessing tunneled plaques with multiple openings or for scalp lesions.","limitations":"Two guidance statements—assessment of tunneled plaques with multiple openings and assessment of scalp lesions—did not reach consensus.","practice_takeaway":"Adopt the consensus lesion definitions and guidance in HS trial protocols and investigator training to standardize assessments, while applying caution to tunneled plaques with multiple openings and scalp lesions where consensus was not achieved."}}],"initialOffset":35,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"Hidradenitis Suppurativa"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"Hidradenitis Suppurativa"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"Hidradenitis Suppurativa"}}}]]

Papers